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Heavy menstrual bleeding (HMB) is a common complaint negatively affecting 
women’s quality of life. Modern intrauterine treatment modalities for HMB, 
namely levonorgestrel-releasing intrauterine system (LNG-IUS) and 
endometrial ablation, have changed significantly the management of HMB 
and resulted in a marked decrease in the number of hysterectomies in many 
countries. Despite the increasing popularity of these treatments, little is 
known about the cancer risks among women treated with these methods. Also, 
some women need a later hysterectomy after endometrial ablation, but factors 
predisposing to that are insufficiently known. To assess the cancer risk among 
women treated for HMB with LNG-IUS or endometrial ablation, and to 
evaluate the risk factors for postablation hysterectomy, we conducted four 
nationwide register-based cohort studies. 
In the LNG-IUS user studies, a cohort of all Finnish women who had received 
reimbursement for LNG-IUS for the treatment of HMB at age 30–49 years 
during 1994–2007 (n = 93 843) were identified from the Medical 
Reimbursement Register. In the endometrial ablation study, we identified all 
Finnish women who had undergone endometrial ablation at age 30–49 years 
in 1997–2014 from the Hospital Discharge Register (n = 5 484). 
In all studies, the study subjects were followed for the cancer of interest with 
the aid of the Finnish Cancer Registry. The risk of cancer was compared with 
that of the background population. In the endometrial ablation study, 
postablation hysterectomy rate was compared with that of the control cohort 
(n = 26 938) extracted from the Population Register Centre. A multivariate 
Poisson regression model was used to evaluate the risk factors for postablation 
hysterectomy. 
The data on deaths and emigrations during the follow-up in all studies, and 
the information on live deliveries in the endometrial ablation study, were 
received from the Population Register Centre. Information on surgical 
procedures were obtained in all studies from the Hospital Discharge Register. 
The study subjects were followed from the index date to the end of the study, 
emigration, or death, whichever occurred first. Depending on the cancer, 
additional censoring was done at the date of hysterectomy, bilateral/unilateral 
salpingectomy, or salpingo-oophorectomy. 
The use of LNG-IUS for HMB was associated with an increased risk of breast 
cancer (standardized incidence ratio, SIR 1.19, 95% confidence interval (CI) 
1.13–1.25). In absolute numbers, this means 2-4 excess cases of breast cancer 
per 1 000 LNG-IUS users followed for ten years. The LNG-IUS users with two 




general population (SIR 1.40, 95% CI 1.24–1.57). The risk of both invasive 
lobular cancer (SIR 1.33, 95% CI 1.20–1.46) and ductal cancer (SIR 1.20, 95% 
CI 1.14–1.25) was increased among LNG-IUS users. After two or more LNG-
IUS purchases, the SIR for invasive lobular cancer was 73% higher than in the 
general population (SIR 1.73, 95% CI 1.37–2.15). Most invasive breast cancers 
among LNG-IUS users were localized but after 5 years of follow-up, the risk of 
non-localized breast cancers was also statistically significantly higher among 
LNG-IUS users than in the general population. 
The risk of endometrial cancer among LNG-IUS users was significantly 
decreased compared with the background population (SIR 0.46, 95% CI 0.33–
0.64). In absolute numbers, this means 3-6 prevented endometrial cancers per 
10 000 LNG-IUS users followed for ten years. After two or more LNG-IUS 
purchases, the risk was 75% lower than among the general population (SIR 
0.25, 95% CI 0.05–0.73). 
Among LNG-IUS users, the risk of ovarian cancer was up to 41% lower 
compared with the general population (SIR 0.59 (95% CI 0.47–0.73). In 
absolute numbers, this means 3-6 prevented invasive ovarian cancers per 
10 000 LNG-IUS users followed for ten years.  The risk was decreased for all 
epithelial ovarian cancers, most clearly for mucinous carcinoma (SIR 0.49, 
95% CI 0.24–0.87). LNG-IUS use was also associated with a decreased risk of 
borderline ovarian tumors (SIR 0.76, 95% CI 0.57–0.99). The risk of primary 
fallopian tube carcinoma was not increased among LNG-IUS users (SIR 1.22, 
95% CI 0.49–2.50). Of all other cancers, LNG-IUS users had significantly 
lower risk of lung cancer (SIR 0.68, 95% CI 0.49–0.91) and pancreatic cancer 
(SIR 0.50 (95% CI 0.28–0.81). 
Among women with endometrial ablation, the incidence of endometrial cancer 
was not increased compared with the background population (SIR 0.56, 95% 
CI 0.12–1.64). The risk of breast cancer after endometrial ablation was similar 
to that of the general population (SIR 0.86, 95% CI 0.67–1.09). 
A hysterectomy was performed for 19.8% of women treated with endometrial 
ablation during the follow-up (mean 7.3 years, maximum 18 years). The risk 
factors for postablation hysterectomy were leiomyomas, young age, and a 
history of two or more cesarean deliveries or sterilization. 
In conclusion, the use of LNG-IUS for HMB was associated with elevated risk 
of breast cancer but decreased risk of both endometrial and ovarian cancer. If 
the increased breast cancer risk among LNG-IUS users is caused by LNG-IUS 
itself or by other risk factors particularly characteristic to women with HMB is 
not yet known. Endometrial ablation is a good alternative for selected women 
with HMB as most treated women can avoid postablation hysterectomy. Also, 
cancer risks after endometrial ablation seem to be comparable with those of 




are effective, but an individual risk–benefit assessment is important to do 






Runsaat kuukautiset ovat yleinen ongelma, joka vaikuttaa haitallisesti naisen 
elämänlaatuun. Uudet hoitomenetelmät, hormonikierukka ja kohdun 
limakalvon tuhoaminen (endometriumablaatio), ovat merkittävästi 
muuttaneet runsaiden kuukautisten hoitoa, mikä on huomattavasti 
vähentänyt kohdunpoistoja monessa eri maassa. Huolimatta näiden uusien 
hoitokeinojen lisääntyneestä käytöstä, niiden vaikutuksesta naisen 
myöhempään syöpäriskiin on vasta vain vähän tietoa. Kaikki eivät myöskään 
saa riittävää apua vuotoihinsa hormonikierukalla tai endometriumablaatiolla. 
Niitä tekijöitä, jotka ennakoivat lisääntynyttä riskiä joutua myöhempään 
kohdunpoistoon endometriumablaation jälkeen ei vielä kunnolla tunneta. 
Tämän väitöskirjatyön tavoitteena oli tutkia runsaiden kuukautisten hoitoon 
hormonikierukkaa käyttäneiden tai endometriumablaatiolla hoidettujen 
naisten myöhempää syöpäriskiä sekä arvioida, mitkä tekijät ennakoivat 
lisääntynyttä riskiä endometriumablaation jälkeiseen kohdunpoistoon. 
Tutkimukset suoritettiin kansallisina rekisteritutkimuksina. 
Hormonikierukkaa ja syöpäriskiä koskevissa töissämme keräsimme tiedot 
Kelan lääkekorvausrekisteristä kaikista suomalaisista naisista, jotka olivat 30-
49 -vuotiaina käyttäneet hormonikierukkaa runsaiden kuukautisten hoitoon 
vuosina 1994-2007 (93 843 naista). Endometriumablaatiotyössämme 
keräsimme tiedot niistä suomalaisista naisista, joille oli 30-49 -vuotiaana 
tehty endometriumablaatio (5 484 naista). Kaikissa osatöissämme 
vertasimme tutkimusväestön syöpäsairastuvuutta vastaavan ikäiseen 
taustaväestöön Suomen Syöpärekisterin tietojen avulla. 
Endometriumablaatiotyössämme kohdunpoistoriskiä tutkittiin vertailemalla 
endometriumablaation jälkeen tehtyjä kohdunpoistoja 
Väestörekisterikeskuksesta poimitun vertailuväestön (26 938 naista) 
kohdunpoistolukuihin. Kohdunpoiston riskitekijöitä analysoitiin Poissonin 
monimuuttuja-analyysillä. 
Tiedot tutkimusaineistoomme kuuluneiden naisten kuolemista, maasta 
poismuutosta sekä elävänä syntyneistä lapsista saatiin 
Väestörekisterikeskuksesta. Tiedot kirurgisista toimenpiteistä saatiin 
Terveyden ja hyvinvoinnin laitoksen Poistoilmoitusrekisteristä. Seuranta-aika 
alkoi indeksipäivästä ja jatkui tutkimuksen sulkuaikaan, maasta 
poismuuttoon tai kuolemaan, riippuen mikä näistä tapahtui ensin. 
Syöpätyyppikohtaisesti seuranta lopetettiin myös kohdunpoistoon, toisen tai 
molempien munasarjojen ja/tai munatorvien poistoon. 
Hormonikierukkaa runsaiden vuotojen hoitoon käyttäneillä naisilla todettiin 
lisääntynyt riski sairastua rintasyöpään (SIR 1.19, 95% luottamusväli 1.13-
1.25). Tämä tarkoittaa 2-4 ylimääräistä rintasyöpää 1000 hormonikierukan 




vähintään kaksi kertaa hormonikierukan, oli 40% korkeampi 
rintasyöpäsairastuvuus kuin muilla naisilla (SIR 1.40, 1.24-1.57). Riski oli 
kohonnut sekä lobulaariseen (SIR 1.33, 1.20-1.46) että duktaaliseen 
rintasyöpään (SIR 1.20, 1.14-1.25). Vähintään kaksi hormonikierukkaa 
ostaneilla oli 73% korkeampi riski lobulaariseen rintasyöpään kuin 
taustaväestöllä (SIR 1.73, 1.37-2.15). Suurin osa hormonikierukan käyttäjien 
rintasyövistä todettiin paikallisina, mutta viiden vuoden seuranta-ajan jälkeen 
myös levinneen rintasyövän riski oli suurempi kuin muilla naisilla. 
Hormonikierukan käyttäjillä oli taustaväestöä selvästi pienempi 
kohdunrungon syöpäriski (SIR 0.46, 0.33-0.64). Tämä tarkoittaa 3-6 
ehkäistyä kohdunrungon syöpää 10 000 hormonikierukan käyttäjän joukossa 
10 vuoden seurannassa. Vähintään kaksi hormonikierukkaa ostaneilla 
kohdunrungon syöpäriski oli 75% pienempi kuin muilla naisilla (SIR 0.25, 
0.05-0.73). 
Munasarjasyövän riski oli hormonikierukan käyttäjillä 41% pienempi kuin 
taustaväestöllä (SIR 0.59, 0.47-0.73), mikä tarkoittaa 3-6 ehkäistyä 
munasarjasyöpää 10 000 hormonikierukan käyttäjän joukossa 10 vuoden 
seurannassa. Hormonikierukan käyttäjillä oli pienentynyt riski kaikkiin 
epiteliaalisiin munasarjasyöpiin, mutta selvimmin musinoosiin karsinoomaan 
(SIR 0.49, 0.24-0.87). Hormonikierukan käyttäjillä oli myös muita vähemmän 
munasarjojen rajalaatuisia (borderline) kasvaimia (SIR 0.76, 0.57-0.99). 
Munatorvisyövän riski ei ollut hormonikierukan käyttäjillä lisääntynyt (SIR 
1.22, 0.49-2.50). Hormonikierukan käyttäjillä oli pienentynyt riski sairastua 
keuhkosyöpään (SIR 0.68, 0.49-0.91) ja haimasyöpään (SIR 0.50, 0.28-0.81). 
Endometriumablaation jälkeen ei todettu lisääntynyttä riskiä kohdunrungon 
syöpään (SIR 0.56, 0.12-1.64). Myös rintasyöpäriski oli 
endometriumablaatiolla hoidetuilla taustaväestöä vastaava (SIR 0.86, 0.67-
1.09). 
19.8% :lle tehtiin kohdunpoisto endometriumablaation jälkeen seuranta-
aikana (keskiarvo 7.3 vuotta, maksimi 18 vuotta). Kohdunpoiston 
riskitekijöitä olivat kohdun myoomat, nuori ikä, aiemmat keisarileikkaukset 
tai sterilisaatio. 
Johtopäätöksenä voidaan todeta, että hormonikierukkaa runsaiden 
kuukautisten hoitoon käyttäneillä naisilla oli lisääntynyt riski sairastua 
rintasyöpään, mutta vähentynyt riski kohdunrungon- ja munasarjasyöpään. 
Sitä, johtuuko lisääntynyt rintasyöpäriski juuri hormonikierukasta, vai näillä 
naisilla esiintyvistä muista tekijöistä, ei vielä tiedetä. Endometriumablaatio on 
hyvä hoitokeino osalle potilaista, sillä suurin osa endometriumablaatiolla 
hoidetuista ei tarvitse myöhempää kohdunpoistoa. Molemmat näistä 
runsaiden kuukautisten kohdunsisäisistä hoitomuodoista ovat tehokkaita, 






Heavy menstrual bleeding (HMB) is a common problem affecting 30% of 
women in their reproductive years (Fraser et al. 2015). Due to modern and 
effective family planning, each woman experiences approximately 400 
episodes of menstrual bleeding during her lifetime in developed countries 
(Maybin and Critchley 2015). Without effective treatment of heavy 
menstruation, excessive blood loss can cause anemia, have a major negative 
impact on a woman’s quality of life, and cause socioeconomic consequences. 
Due to this worldwide common and demanding gynecological condition, 
efficient and safe treatment options are continuously needed. 
Hysterectomy was the treatment of choice for HMB in earlier decades, but its 
complication risks and costs are not acceptable, as conservative treatments are 
equally efficient in most cases (Hurskainen et al. 2001). It is also notable that 
half the women treated with hysterectomy for HMB are found to have a normal 
uterus (Duckitt 2015). Alongside these facts, a more conservative treatment 
approach for HMB has emerged especially in the last two decades. 
The primary choices to treat HMB are either medical treatment or mini-
invasive surgery. Medical management options are combined oral 
contraceptive (COC) pills, tranexamic acid, non-steroidal anti-inflammatory 
drugs (NSAIDs), or the use of a levonorgestrel-releasing intrauterine system 
(LNG-IUS). 
LNG-IUS was launched in the 1990s for contraception but soon its 
effectiveness on HMB was noticed and HMB became an indication for LNG-
IUS use. The use of LNG-IUS has increased markedly during the last decades 
(Heikinheimo and Fraser 2017). Since its launch, over 43 million LNG-IUSs 
have been sold globally (information from Bayer Oy, Turku, Finland). In 
Finland, currently approximately one-fifth of fertile-aged women use an LNG-
IUS (information from Bayer Oy, Turku, Finland). 
The effect of LNG-IUS is based on its local intrauterine delivery of a potent 
progestin, levonorgestrel, into the lining of the uterine cavity, the 




menstrual bleeding so markedly that most women do not have menstruation 
during use of LNG-IUS (Guttinger and Critchley 2007). The effectiveness of 
LNG-IUS on heavy menstruation has made LNG-IUS the first-line option for 
the treatment of HMB in many countries (Current Care Guidelines 2009, 
Lethaby et al. 2015, Bitzer et al. 2015, Davies and Kadir 2017, Heikinheimo 
and Fraser 2017), and it has been reflected as significantly declined rates of 
hysterectomies. In Finland, the rate of hysterectomies for HMB has decreased 
by over 50% during the last two decades (Finnish National Institute for Health 
and Welfare). 
Despite the effectiveness of hormonal treatment for menstrual blood loss, one 
concern is the possible effect on later cancer risk. Lately, in particular, the role 
of progestogens on the cancer risk has been cleared. The carcinogenic effect of 
progestogens seems to depend on the tissue and progestogen type used. Also, 
the progestogen concentration and duration of delivery, as well as the age of 
the woman may have an impact on cancer risk. In breast tissue, progestogens 
can act as mitogens and a long-term use of progestogens, both in the form oral 
hormonal contraception or postmenopausal hormone therapy (HT), is 
associated with an increased risk of breast cancer (CGHFBC 1996, IARC 2012, 
Stanczyk et al. 2013, Lambrinoudaki 2014, Bassuk and Manson 2015). An 
increased risk of breast cancer has also been reported in postmenopausal 
LNG-IUS users (Lyytinen et al. 2010). In contrast to breast tissue, 
progestogens have an antiproliferative effect in the endometrium and ovaries 
(Diep et al. 2015). Whether the breast tissue and other organs react similarly 
for exogenous progestogens in both fertile-aged and postmenopausal women, 
is not well known. Although the effect of LNG-IUS is based on the high 
intrauterine levonorgestrel concentration, some levonorgestrel is also released 
into the systemic circulation (Luukkainen et al. 1990, Hidalgo et al. 2009, 
Seeber et al. 2012). The effect of premenopausally used LNG-IUS on the risk 
of cancers, especially endometrial and breast cancer, is insufficiently known 
(Backman et al. 2005, Dinger et al. 2011, Heikkinen et al. 2016a). 
To avoid the risks of major surgery associated with hysterectomy, and to avoid 
the side effects of hormones, mini-invasive treatment for HMB using 




Endometrial ablation is suitable only for women who do not desire future 
pregnancies. In endometrial ablation, the endometrium is largely destroyed. 
In the 1980s, hysteroscopic methods (laser, freezing, and electroresection) 
were used, but in the last two decades, safer non-hysteroscopic methods using 
microwaves, radiofrequencies, free heated liquid, or thermal balloon have 
replaced the older methods (Kumar et al. 2016). 
The long-term effect of endometrial ablation on menstrual bleeding is 
comparable with that of LNG-IUS in most women, but some women still need 
subsequent hysterectomy after endometrial ablation. How the destruction of 
endometrium affects later cancer risk, especially risk of uterine and 
gynecological cancers, is sparsely studied. Also, the incidence of breast cancer 
among women treated with endometrial ablation is unknown. 
All this encouraged us to study the cancer risks among women suffering from 
heavy menstruation and treated with either LNG-IUS or endometrial ablation. 
We also wanted to evaluate the need for later hysterectomy, as well as the 
factors predicting for hysterectomy after endometrial ablation. We were able 
to study these topics using data of excellent quality and high coverage from 




Review of the literature 
Heavy menstrual bleeding 
Heavy menstrual bleeding (HMB) represents the most common form of 
abnormal uterine bleeding (AUB) in women of reproductive age (Munro et al. 
2011, Whitaker and Critchley 2016). Without effective treatment, HMB limits 
normal activities, significantly impairs the quality of life (Hurskainen et al. 
2001, Heliövaara-Peippo et al. 2013), and forms a significant cost burden for 
both the patient and the healthcare system (Jensen et al. 2012). 
Historically, HMB has been defined as an objective blood loss over 80 mL per 
cycle (Hallberg et al. 1966). However, this definition has been questioned due 
to the difficulty in assessing menstruation blood loss objectively. Also, it has 
been suggested that HMB is a manifestation caused by heterogeneous 
etiologies and thus represents more a symptom, rather than a diagnosis 
(Munro et al. 2011). 
To standardize the terminology of AUB used in clinical practice and research, 
a new classification of AUB was launched by the International Federation of 
Gynecology and Obstetrics (FIGO) in 2011 (Munro et al. 2011). However, this 
classification is still not widely used by clinicians, nor has it had an impact on 
the diagnosis codes. In the new FIGO terminology, previously used 
“menorrhagia” has been replaced by “heavy menstrual bleeding” to describe 
excessive menstruation (Munro et al. 2011). According to the new 
classification, HMB is a symptom that can exist irrespective of the frequency, 
duration, or regularity of menstrual bleeding (Munro et al. 2011). Also, the new 
classification of HMB is based on a woman’s subjective perception of excessive 
menstrual bleeding and its negative impact on the quality of her life (Munro et 
al. 2011, NICE 2016). According to this classification, AUB is categorized by its 
causes as related or unrelated to uterine structural abnormalities and is 
classified by one or more letters that indicate the cause. The acronym PALM-




Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, and Not 
otherwise classified) is composed of the first letters of the causes of AUB 
(Munro et al. 2011). The PALM group includes structural abnormalities which 
can be visualized or histologically diagnosed. The COEIN group consists of 
nonstructural causes of AUB. 
HMB can result from a multifactorial cause or solely from an endometrial 
cause. In up to 20% of cases, excessive menstrual blood loss is caused by a 
systemic disorder of coagulation (AUB-C) (Davies and Kadir 2017), most often 
by von Willebrand disease (Shankar et al. 2004). Ovulatory dysfunction 
associated with chronic unopposed estrogen, commonly caused by obesity or 
polycystic ovary syndrome (PCOS) (ACOG 2013, Nandi et al. 2014, 
Hapangama and Bulmer 2016), is a frequent cause of irregular HMB (AUB-
O). The mechanism of HMB can also be a primary disorder of the 
endometrium (AUB-E). In AUB-E, abnormalities occur in endometrial 
hemostasis, such as an altered local production of endometrial prostaglandins 
and cytokines, decreased endometrial vasoconstriction, increased destruction 
of the extracellular matrix, or delayed local repair response in the 






Medical treatment of heavy menstrual bleeding 
 
HMB can be treated either medically or surgically. The management of HMB 
depends on the woman’s age, desire to preserve fertility, and the possible 
findings of pelvic pathology. In the absence of significant pelvic pathology, 
medical management of HMB (LNG-IUS, progestogen-containing oral 
preparations, and oral hemostatic therapies) can be considered as the primary 
choice (RCOG 2008, Current Care Guidelines 2009, NICE 2016). 
Levonorgestrel-releasing intrauterine system (LNG-IUS) 
 
Initial study and design of LNG-IUS took place in the 1970s–1980s (Nilsson 
et al. 1981) and the first LNG-IUS (Mirena®, Bayer Oy, Turku, Finland) was 
approved for contraception in Finland in 1990 (Luukkainen et al. 1990), and 
later in other countries. Very soon the effectiveness of LNG-IUS for HMB was 
noted (Andersson et al. 1994, Lähteenmäki et al. 1998), and since 1991 LNG-
IUS has been approved for treatment of HMB in Finland (information from 
Bayer Oy, Turku, Finland). LNG-IUS (Mirena®, Bayer Oy, Turku, Finland) is 
currently authorized to be marketed in 128 countries. In 124 countries, LNG-
IUS (Mirena®, Bayer Oy, Turku, Finland) is registered for use for idiopathic 
menorrhagia (information from Bayer Oy, Turku, Finland). In most of these 
countries, LNG-IUS is also used for endometrial protection during estrogen 
therapy (ET) (Depypere and Inki 2015). LNG-IUS is the most effective medical 
treatment for HMB and is currently recommended as the first-line treatment 
for HMB in many countries (Current Care Guidelines 2009, Lethaby et al. 
2015, Bitzer et al. 2015, Davies and Kadir 2017, Heikinheimo and Fraser 2017). 
The effectiviness of LNG-IUS on HMB has increased the popularity of its use 
(Heikinheimo and Fraser 2017). Since launch, more than 43 million LNG-
IUSs have been sold globally (information from Bayer Oy, Turku, Finland). In 
Finland, currently approximately one-fifth of fertile-aged women use LNG-




During the last decade, two newer LNG-IUSs with less levonorgestrel have 
been launched (Jaydess® and Kyleena®, Bayer Oy, Turku, Finland). 
However, still only one LNG-IUS is approved for the treatment of HMB and 
for endometrial protection during ET (Mirena®, Bayer Oy, Turku, Finland), 
and the other LNG-IUSs (Jaydess® and Kyleena®, Bayer Oy, Turku, Finland) 
are approved only for contraceptive use. 
In this thesis, the focus is solely on the LNG-IUS used for HMB (Mirena®, 
Bayer Oy, Turku, Finland) (Figure 1). 
 
Figure 1. Levonorgestrel-releasing intrauterine system 
(Mirena®). Photo and permission of use from Bayer Oy. 
 
 
Structure of LNG-IUS and mechanism of action 
 
LNG-IUS consists of a T-shaped polyethylene frame with a hormone reservoir 
containing 52 mg levonorgestrel (Mirena®, Bayer Oy, Turku, Finland). 
Progestin is released continuously into the uterine cavity at an initial rate of 
20 μg/day, and the rate of levonorgestrel release declines to 10 μg/day after 
5 years of use. For comparison, the LNG-IUSs containing less progestin, and 
used solely for contraception, release 6 μg/day (Jaydess®) or 9 μg/day 





The effect of LNG-IUS is mediated by the action of a high local concentration 
of levonorgestrel within the endometrium. In the user of LNG-IUS, the 
concentration of levonorgestrel in the endometrium is over 100-fold that in 
the systemic circulation (Nilsson et al. 1982). The local delivery of 
levonorgestrel into the endometrium results in a highly effective suppression 
of endometrial proliferation, which is histologically seen as an inactive 
endometrium with thin epithelium and decidualized stroma. These changes 
result in highly effective contraception and an over 90% decrease in menstrual 
bleeding (Andersson and Rybo 1990, Hurskainen et al. 2001, Mansour 2012). 
Despite the local intrauterine release of levonorgestrel from the LNG-IUS, 
some levonorgestrel is continuously also released into the systemic circulation, 
with mean plasma levels of levonorgestrel between 100–200 pg/mL 
(Luukkainen et al. 1990), but significant variations have been reported 
(Heikinheimo et al. 2006). Systemic levonorgestrel concentration of the LNG-
IUS user is approximately 5–10 times lower than that of an oral levonorgestrel 
contraceptive user, and approximately 2-fold lower than that of a 
levonorgestrel contraceptive implant user (Orme et al. 1983, Sivin 2003). 
 
 
Health benefits of LNG-IUS 
 
In addition to the reduction in menstrual bleeding, and efficient 
contraception, LNG-IUS has many established health benefits (Bahamondes 
et al. 2015). LNG-IUS provides effective protection from endometrial 
hyperplasia during ET (Depypere and Inki 2015). In patients with HMB, LNG-
IUS has been reported to alleviate HMB-related pain and increase the quality 
of life (Heliövaara-Peippo et al. 2013). LNG-IUS has also been reported to 
relieve premenstrual symptoms among women with HMB (Leminen et al. 
2012), and be effective against dysmenorrhea and pelvic pain caused by 







Adverse effects of LNG-IUS 
 
During the first months after LNG-IUS insertion in fertile-aged women, 
transient intermittent or prolonged uterine bleeding or spotting is reported by 
up to 35% (Hurskainen et al. 2001, Mansour 2012) and some experience 
hormonal side effects such as acne, nausea, mood changes, or breast 
tenderness (Andersson et al. 1994, Mansour 2012, Lethaby et al. 2015). 
Uterine perforation is an infrequent but possible complication associated with 
insertion of LNG-IUS (incidence 0.4/1000 sold IUSs) (Kaislasuo et al. 2012). 
Expulsion of LNG-IUS occurs in 0.8–20% of cases (Mansour 2012, Bitzer et 
al. 2015, NICE 2016). An increased incidence of transient functional ovarian 
cysts has been reported among LNG-IUS users (Inki et al. 2002, Mansour 
2012, Lethaby et al. 2015).  
The long-term effects of levonorgestrel exposure from LNG-IUS use on the risk 
of cancers, especially breast cancer (Backman et al. 2005, Lyytinen et al. 2010, 
Dinger et al. 2011, Heikkinen et al. 2016a) or gynecological cancers (Jaakkola 
et al. 2011, Koskela-Niska et al. 2015), are insufficiently known. The issue 
about LNG-IUS and cancer risk will be discussed later in the section 
“Hormonal treatment of heavy menstrual bleeding, and cancer risk.” 
Other medical treatments 
 
Other medical treatments of HMB include various progestogen-containing 
oral preparations (COCs and oral progestins), antifibrinolytic drugs, and 
NSAIDs, used alone or in combination (Bitzer et al. 2015, Maybin and 
Critchley 2016, Davies and Kadir 2017, Heikinheimo and Fraser 2017). 
The effectiveness and adverse effects of various treatments for HMB are shown 






Table 1. Effectiveness and adverse effects of various treatments for heavy menstrual bleeding. 
 






Potential adverse effects 
Hormonal preparations 



















Mood changes, headache, nausea, 
spotting, thromboembolism 
Progestin-only preparations 
Extended cycle progestin 
(menstrual cycle day 5–26 
 or continuously)6,7 
80  Progestogenic side effects, need for 
contraception 




Progestogenic side effects, irregular 
bleeding 
Non-hormonal preparations 
Tranexamic acid10 26–60  Diarrhea, indigestion, headache 










need for sick 
leave  
Residual menstruation, need for 
further contraception, risk of later 
hysterectomy. Surgical complications 
(e.g., infection, hemorrhage, 
perforation; in 0.3–2%). 
Hysterectomy15 100  Surgical complications (e.g., infection, 
thromboembolism, organ perforation; 
in 12–19%) 
COC = combined oral contraceptive, LNG-IUS = levonorgestrel-releasing intrauterine system, NSAID = 
non-steroidal anti-inflammatory drug. 
Data from: 1Larsson et al. 1992, 2Fraser and Kovacs 2003, 3Shaaban et al. 2011, 4Fraser et al. 2011, 
5Fraser et al. 2012, 6Irvine et al. 1998, 7Lethaby et al. 2015, 8Andersson and Rybo 1990, 9Kaunitz et al. 
2009, 10Leminen and Hurskainen 2012, 11Bitzer et al. 2015, 12Bradley and Gueye 2016, 13Kumar et al. 




Surgical treatment of heavy menstrual bleeding 
 
 
Surgical treatment of HMB is an option for those women who do not improve 
with medical treatment or where such treatment is contraindicated, or for 
those with significant pelvic pathology. According to guidelines of many 
countries, mini-invasive surgery with endometrial ablation is currently 
considered the primary surgical option due to the risks of hysterectomy (NICE 
2016, Laberge et al. 2015). In Finland, a guideline for the treatment of HMB 
recommends the use of endometrial ablation only if there are 
contraindications for hysterectomy (Current Care Guidelines 2009). However, 




Mechanism and techniques of endometrial ablation 
 
Endometrial ablation is a minimally invasive procedure where the full 
thickness of endometrium, including the deep basal glands of the uterus, is 
destroyed with energy (e.g., heat), and the uterus is preserved (Lethaby et al. 
2013). The indication for endometrial ablation is HMB due to benign causes 
in women who have completed childbearing (Kumar et al. 2016). 
Contraindications for endometrial ablation include active pelvic infection, 
endometrial hyperplasia, uterine cancer, and pregnancy or desire of future 
pregnancies. Endometrial ablation is also contraindicated in postmenopausal 
women (Laberge et al. 2015, Kumar et al. 2016). Amenorrhea rate is up to 70% 
(Lethaby et al. 2013, Kumar et al. 2016) (Table 1), and satisfaction rate of 77–
96% (Kumar et al. 2016). 
Endometrial ablation was introduced in the late 1980s. The first-generation 
endometrial ablation techniques included hysteroscopic laser or freezing 
ablations, and transcervical endometrial resection (with rollerball or loop). 
From the late 1990s, newer second-generation non-hysteroscopic endometrial 




radiofrequency techniques have replaced the older methods (Lethaby et al. 
2013). These non-hysteroscopic endometrial ablations can be performed in an 
outpatient setting under local anesthesia, are easy to learn, and have shorter 
operating and recovery times and a better safety profile (Kumar et al. 2016).  
The efficacy in reducing menstrual bleeding and patient satisfaction rates are 
similar in the first- and second-generation endometrial ablations in up to 
10 years of follow-up (Lethaby et al. 2013). The cost-effectiveness has been 
reported to be better in the second-generation endometrial ablations 
compared with the first-generation techniques or hysterectomy (Garside et al. 
2004, Miller et al. 2015). Compared with LNG-IUS, endometrial ablation has 
been reported to be inferior in cost-effectiveness (Health Quality Ontario 
2016) but has similar patient satisfaction and greater reduction in menstrual 
bleeding than LNG-IUS at 2 years (Marjoribanks et al. 2016).  
In Finland, endometrial ablation is not common, but in many other countries, 
endometrial ablation is much more common. Currently, approximately 500 
endometrial ablations are performed annually in Finland (Figure 2). In 
England, up to 75% of surgical treatments for HMB were endometrial 
ablations during 2009–2012 (RCOG 2014). 
Figure 2. The annual number of hysterectomies for heavy 
menstrual bleeding and endometrial ablations in Finland during 
1997–2015. Data from the Hospital Discharge Register of the 































































Complications and adverse effects of endometrial ablation 
 
 
Despite the simplicity of the non-hysteroscopic endometrial ablation 
procedure, some complication risks exist. The most common intraoperative 
complications with the second-generation techniques are cervical lacerations, 
nausea and vomiting, and pelvic pain or cramping (NICE 2016). A rare but 
serious complication is uterine perforation with possible visceral injury or 
hemorrhage (NICE 2016). The incidence of uterine perforation with the first-
generation endometrial ablation techniques is 1.5% (Kumar et al. 2016) but it 
is significantly lower with the newer non-hysteroscopic techniques (relative 
risk [RR] 0.32, 95% confidence interval [CI] 0.1–1.0) (Lethaby et al. 2013, 
Lethaby et al. 2015). Postoperatively, a prolonged transient vaginal discharge 
frequently occurs (NICE 2016). Incidence of endometritis is 1.4–2% (Sharp 
2012, Kumar et al. 2016). Pregnancy rate after endometrial ablation has been 
reported to be 0.7–1.4% (Yin 2010, Sharp 2012, Moulder and Yunker 2016). 
Postablation pregnancies have high risks such as fetal anomalies and 
abnormal placentation due to uterine cavity scarring and distortion (Yin 
2010). Due to the major pregnancy complication risks, sterilization is highly 
recommended before endometrial ablation.  
Small areas with viable endometrium may be retained after endometrial 
ablation, which is evidenced by residual menstrual bleeding in some cases. 
These patients may also experience cyclical pain caused by obstructed 
menstruation (hematometra) in the scarred uterus. In some cases, 
endometrial ablation fails to relieve a woman’s symptoms, and later operation 
is needed. A repeat endometrial ablation is not usually recommended due to 
uterine distortion and the lack of data on safety (Laberge et al. 2015). In most 
cases, hysterectomy is the next step after failed endometrial ablation. The 
postablation hysterectomy rate has been reported to be 13–21% (Longinotti et 
al. 2008, El-Nashar et al. 2009, Cooper et al. 2011, Shavell et al. 2012, Bansi-
Matharu et al. 2013, Dood et al. 2014, Wishall et al. 2014).  
The risk factors predisposing to postablation hysterectomy are not well 




Nashar et al. 2009, Shavell et al. 2012, Bansi-Matharu et al. 2013), previous 
cesarean sections (Shavell et al. 2012, Wishall et al. 2014), and leiomyomas 
(Bansi-Matharu et al. 2013, Wishall et al. 2014) have been associated with an 
increased hysterectomy risk. However, the effect of the sizes or locations of 
leiomyomas on the risk of endometrial ablation failure is insufficiently known. 
Also, the possible differences in the long-term efficacy of various second-
generation devices are not well known.  
Due to the regenerated or retained areas of endometrium after endometrial 
ablation, the risk of later endometrial malignancy exists but the magnitude of 
the risk is unknown. The issue of endometrial ablation and cancer risk will be 
discussed later in the section “Surgical treatment of heavy menstrual bleeding, 




Back in 2002, almost half of the hysterectomies worldwide were performed 
due to HMB (Lethaby et al. 2013). However, due to the increasing popularity 
of conservative treatments for HMB, especially LNG-IUS and endometrial 
ablation, the number of hysterectomies has fallen in many countries (Wright 
et al. 2013, Jokinen et al. 2015, Gante et al. 2017). In the USA, the number of 
hysterectomies for benign indications decreased by 36% in 2002–2010 
(Wright et al. 2013). In Finland, over 11 000 hysterectomies were performed 
annually 20 years ago. Today, the total number of hysterectomies is over 50% 
less than in 1997. Also, hysterectomies for HMB have decreased by 50% during 









Figure 3. Hysterectomies in Finland during 1997–2015. Data 
from the Hospital Discharge Register of the Finnish National 




Hysterectomy relieves menstrual bleeding by 100% and has a high satisfaction 
rate, but it carries risks, is costly, and has a long recovery time. In a Finnish 
randomized controlled trial, hysterectomy was associated with a postoperative 
complication rate of 29% (Hurskainen et al. 2001), and a significantly inferior 
cost-effectiveness compared with LNG-IUS use in up to 10 years of follow-up 
(Heliövaara-Peippo et al. 2013). A large prospective study in Finland reported 
a total complication rate of 12–19% in hysterectomies, and a major 
complication (such as injury to bowel or vascular structure) rate of 3–4% 
(Brummer et al. 2011). The long-term adverse effects of hysterectomy are 
increased risk of pelvic organ prolapse (Lykke et al. 2016) and urinary 
incontinence (Altman et al. 2007, Cooper et al. 2011, Heliövaara-Peippo et al. 
2010). Also, hysterectomy has been associated with an increased risk of 
impaired ovarian function with early menopause (Halmesmäki et al. 2004, 
Farquhar et al. 2005) and the effects of hysterectomy on cardiovascular 
functions are unknown (Marjoribanks et al. 2016). It is widely recommended 
that major surgical treatment of HMB should be reserved for women 
unresponsive to medical treatment of HMB or those with significant uterine 




































































Cancer among women 
Epidemiology of cancers among women 
 
 
Globally, over 6.7 million new cancers are diagnosed annually among the 
female population. In Finland, 16 1oo new cancers are diagnosed among 
women (www.cancerregistry.fi). Cancer is the leading cause of death 
worldwide among fertile-aged women. In developed countries, such as 
Finland, the incidence of female cancers has been increasing due to changes 
in lifestyle (i.e., decreased parity, increased obesity, and increased alcohol 
consumption), population-based cancer screenings, and prolonged life 
expectancy resulting in a greater proportion of women in older age groups 
(Figure 4). 
Figure 4. New cancer cases (incidence) among all Finnish 









Breast cancer is the most frequently diagnosed cancer among women. 
Worldwide, a total of 1.7 million new breast cancers are diagnosed every year. 
In developed countries, the cumulative lifetime incidence of breast cancer is 
approximately 10–12% (Ferlay et al. 2012, Rojas and Stuckey 2016) meaning 
that 1 in 8–10 women is diagnosed with breast cancer during their lifetime 
(Ferlay et al. 2012, Rojas and Stuckey 2016). In 2014, a total of 5008 new 
breast cancers were diagnosed in Finland, with an incidence of 95.7/100 000 
women-years, adjusted for age of the World Health Organization’s world 
standard population (Figure 4). In addition, a total of 406 precursors of 
invasive cancer – in situ carcinoma tumors of the breast – were diagnosed in 
2014 in Finland. Most breast cancers occur among women aged 60–64 years, 
but 25% of new cases are diagnosed in women under 50 years (Figure 5) 
(www.cancer.fi). 
Figure 5. Diagnosed new breast cancers in Finland by age 








































Postmenopausal breast cancer incidence has been growing in Finland and in 
other countries (Ferlay et al. 2012) but incidence among those under 65 years 
of age has been stable in Finland (Ferlay et al. 2012). Due to effective 
population-based screening programs with mammographies, and improved 
treatments, survival of breast cancer has improved in recent decades (Sant et 
al. 2015). In Finland, the relative 5-year survival rate was 93% for women aged 
both under and over 55 years in 2012–2014 (www.cancer.fi). Despite 
improved survival, breast cancer remains the leading cause of cancer death 
among premenopausal women, which has been suggested to be attributable to 
more aggressive disease characteristics, later stage of disease at diagnosis, and 
lack of population-based screening (Ferlay et al. 2012, Azim and Partridge 
2014) (Figure 6). 
Figure 6. Cancer deaths among women aged under 55 years in 







Breast cancer is a heterogeneous disease with many histological subtypes: up 
to 80% of invasive breast cancers are of ductal histology, 15% lobular, and the 
remaining 5% other less common histologies (Tavassoli 2003). Since the 
2000s, in addition to histological subtypes, breast cancer tumors are 
considered to consist of at least four different molecular subtypes: luminal A 
(estrogen receptor [ER] or progesterone receptor [PR] positive, or both, 
human epidermal growth factor receptor 2 [HER2] negative, low 
proliferation), luminal B (ER or PR positive, or both, HER2 negative, high 
proliferation), HER2-enriched, and basal-like tumors (HER2 negative, and 
ER and PR negative; triple-negative breast cancer) (Perou et al. 2000, Sorlie 
et al. 2001). Young women tend to more frequently have more aggressive 
breast tumors including basal-like, HER2 positive, and tumors with higher 
grade than in postmenopausal women (Azim and Partridge 2014).  
Breast cancer is a hormone-related cancer and is associated with many genetic, 
reproductive, and lifestyle factors (Rojas and Stuckey 2016). Many of the 
protective or risk factors are associated with endogenous or exogenous 
hormones (Rojas and Stuckey 2016). There is consistent evidence that long-
term HT including progestogen and COCs increases the risk of breast cancer 
(IARC 2012, Gierisch et al. 2013, Bassuk and Manson 2015, Chlebowski et al. 
2015). In general, parity and breastfeeding are protective factors, whereas 
young age at menarche, and late menopause increase the risk of breast cancer 
(Rojas and Stuckey 2016). The highest risk of breast cancer is among women 
with first-degree relatives with breast cancer (Nelson et al. 2012, Rojas and 
Stuckey 2016). Also, lifestyle factors such as alcohol consumption, sedentary 
lifestyle, and smoking are associated with increased risk of breast cancer 
(Rojas and Stuckey 2016). Obesity is a significant risk factor for 
postmenopausal breast cancer, but no effect or a decrease in risk is seen for 
premenopausal breast cancer (Benedetto et al. 2015). Up to 10% of breast 
cancers are due to mutations in breast cancer susceptibility genes. Mutations 
in breast cancer susceptibility genes type 1 or 2 (BRCA1 or BRCA2 genes) 







Endometrial cancer is the fourth most common cancer following breast, colon, 
and lung cancers, and the most common gynecological cancer among women 
in developed countries (www.cancer.fi) (Ferlay et al. 2012). Annually, 850 new 
endometrial cancers are diagnosed in Finland (www.cancer.fi) (Engholm et al. 
2016). The age-adjusted annual incidence of endometrial cancer in Finland is 
13.2/100 000 women-years (Figure 4). Most cases are diagnosed in women 
over 60 years but 5% occur in women under 50 years (www.cancer.fi) 
(Figure 7). In the USA, the incidence of endometrial cancer at young ages is 
significantly higher; 24% of new cases occurred in women under 55 during 
2009–2013 (SEER 2013). The incidence of endometrial cancer has alarmingly 
increased at all ages in developed countries, mainly due to longevity and the 
epidemic of obesity (Renehan et al. 2010, Kamal et al. 2016). The incidence of 
endometrial cancer is predicted to increase by 30% among women over 
65 years by the year 2025 in Finland (Ferlay et al. 2012). 
Figure 7. Diagnosed new gynecological cancers in Finland, 

























Endometrial cancers are divided into well-, moderately-, and poorly 
differentiated estrogen-related type 1 cancer, and more aggressive, non-
estrogen dependent type 2 cancer (Bokhman 1983). Type 1 cancers account for 
60–70% of new cases and are usually low grade with endometrioid histology, 
arise from endometrial hyperplasia, and have better prognosis (Murali et al. 
2014). Type 2 endometrial carcinomas occur typically in older women and are 
usually higher grade with non-endometrioid histology, and have a poor 
prognosis (Tran and Gehrig 2017). The increased incidence of endometrial 
cancer is mostly due to the increased numbers of type 1 cancer, while the 
incidence of type 2 cancer has not significantly changed (Duong et al. 2011). 
Endometrial cancer commonly presents with postmenopausal bleeding or 
AUB in younger women. The incidence of endometrial cancer among 
premenopausal women with AUB is unknown. 
Unopposed exogenous or endogenous estrogen exposure is an established risk 
factor and the most conspicuous driver of type 1 endometrial cancer. Obesity, 
PCOS, and anovulatory menstrual cycles are states with chronic unopposed 
estrogenic effect and are associated with an elevated risk of endometrial cancer 
(Schindler 2009, Kamal et al. 2016). Estrogen overload without adequate 
progestogen effect in the endometrium results in endometrial proliferation 
and eventually hyperplastic changes in the endometrium. Endometrial 
hyperplasia with atypia and endometrial intraepithelial neoplasia are 
precursors of endometrial cancer with significant risk of progression to 
carcinoma (Kurman et al. 1985, Lacey and Chia 2009, Sanderson et al. 2016). 
Other risk factors include early menarche, nulliparity, late menopause, and 
postmenopausal tamoxifen use (Saso et al. 2011, Kamal et al. 2016). A risk 
population for endometrial cancer are women with Lynch syndrome 
(hereditary nonpolyposis colon cancer). They have a lifetime risk of 
endometrial cancer of up to 71%, with average age of 49 at cancer diagnosis 
(Singh and Resnick 2017). 
Endometrial cancer has a good prognosis if diagnosed early. The 5-year 
survival for stage I endometrial cancer is approximately 92%, but for stages III 






Ovarian cancer is the fifth most common cancer in women in the developed 
world and the most lethal of gynecological cancers (Ferlay et al. 2012, Torre et 
al. 2017) (Figure 6). In Scandinavian countries, the incidence of ovarian cancer 
is the highest in the world (Engholm et al. 2016, Torre et al. 2017). In 2014, 
the incidence of ovarian cancer in Finland was 9.5/100 000 women-years 
(Figure 4). A total of 421 ovarian cancers and 191 precursors of ovarian cancer 
(borderline ovarian tumors) were diagnosed in Finland (www.cancer.fi). Most 
ovarian cancers are diagnosed among women aged 65–69 years 
(www.cancer.fi) (Figure 7).  
Ovarian cancers are classified as epithelial, sex cord stromal, and germ cell 
tumors (Jayson et al. 2014). Epithelial ovarian cancer is the most predominant 
form of ovarian cancer (80–90%) and is divided into different 
histopathological classes: serous (68–71% of all epithelial carcinomas), clear 
cell (12–13%), endometrioid (9–11%), mucinous (3%), mixed (6%), and 
transitional (1%) carcinomas (McCluggage 2011). Since 2014, serous ovarian 
carcinoma has been further divided into high-grade and low-grade subtypes 
(Kurman et al. 2014, Prat and FIGO Committee on Gynecologic Oncology 
2014), which are considered as distinct tumors with different etiology, 
morphology, and behavior (McCluggage 2011). The origin of high-grade serous 
ovarian carcinoma is proposed not to be in the ovary but in the fimbriae of the 
fallopian tubes (serous tubal intraepithelial carcinoma of the fallopian tube) 
(Crum et al. 2012). 
The different epithelial ovarian tumor subtypes are suggested to arise from 
different tissue origins and their etiologies and risk factors vary. The theories 
of general mechanisms behind the ovarian cancer are incessant ovulation 
theory (Fathalla 1972), the gonadotropin theory (Stadel 1975, Cramer and 
Welch 1983), the retrograde menstruation or inflammatory theory (Cramer 
and Xu 1995), fallopian tube as an origin theory (Crum et al. 2007), and the 
newest, dual pathway theory (Kurman and Shih 2010). According to the dual 




behavior and morphology. Type 1 tumors consist of low-grade serous, low-
grade endometrioid, clear cell, mucinous, and transitional (Brenner) tumors. 
Type 1 tumors are indolent and slowly growing tumors arising from borderline 
tumors and have a good prognosis (Kurman and Shih 2010). Type 2 tumors 
consist of high-grade serous carcinomas, undifferentiated carcinomas, and 
malignant mixed mesodermal tumors (carcinosarcomas). Type 2 tumors are 
highly aggressive, rapidly growing, and are usually diagnosed at an advanced 
stage (Kurman and Shih 2010). 
Several protective and risk factors for ovarian cancer exist, but these may differ 
according to the subtypes of ovarian cancer. The most established protective 
factors are the use of COC, parity, tubal ligation, salpingectomy, and 
hysterectomy (Hinkula et al. 2006, Cibula et al. 2011, Havrilesky et al. 2013, 
Falconer et al. 2015, Madsen et al. 2015). The risk factors for ovarian cancer 
include advanced age, family history of ovarian cancer, HT use, nulliparity, 
and infertility (Adami et al. 1994, Ness et al. 2002, Koskela-Niska et al. 2013b, 
Jervis et al. 2014). Also, endometriosis has been suggested as a risk factor for 
ovarian cancer (Heidemann et al. 2014). However, some subtypes of ovarian 
cancer differ according to their risk factors. One of these is mucinous ovarian 
cancer, incidence of which seems not to be decreased by COCs (Schuler et al. 
2013) but is reported to be decreased by postmenopausal ET use (Koskela-
Niska et al. 2013b). Populations at significantly high risk of ovarian cancer are 
BRCA1 or BRCA2 mutation carriers who have a 40–60% lifetime risk of 
epithelial ovarian cancer (Mavaddat et al. 2013, Jayson et al. 2014). 
Unfortunately, the vast majority of ovarian cancers are diagnosed at an 
advanced stage (Finnish Cancer Registry). A delayed diagnosis results from 
lack of effective screening and nonspecific symptoms of ovarian cancer, which 
include abdominal pain/bloating and distention, urinary urgency, alterations 
in bowel function, or an abdominal mass (Puistola and Leminen 2013, Jayson 
et al. 2014). Despite advances in treatment, ovarian cancer has the poorest 
prognosis of all gynecological cancers, with an overall 5-year survival of 45% 





Due to the highest prevalence of epithelial ovarian tumors, I focus on these in 
this thesis. 
 
Primary fallopian tube carcinoma 
 
Primary fallopian tube carcinoma (PFTC) is a rare and aggressive malignancy, 
constituting approximately 1% of gynecological malignancies (Kalampokas et 
al. 2013) with worldwide incidence of 0.36/100 000 women-years 
(Kalampokas et al. 2013). In Finland during 2010–2014, the incidence of PFTC 
was 0.7/100 000 women-years with 205 new cases (Finnish Cancer Registry). 
PFTC most commonly occurs in women aged 40–65 years (mean 55 years) 
and 75% of PFTCs are postmenopausal (Kalampokas et al. 2013). PFTC is a 
distinct malignancy but the differentiation of PFTC from epithelial ovarian 
cancer is sometimes difficult due to similar histological appearance 
(Kalampokas et al. 2013). 
The etiology and risk factors of PFTC are not well known, but multiparity and 
use of COCs are associated with decreased risk (Riska et al. 2007, Riska and 
Leminen 2007, Kalampokas et al. 2013). Nulliparity, long-term 
postmenopausal HT, also in the form of LNG-IUS, have been reported to 
increase the risk of PFTC (Riska and Leminen 2007, Koskela-Niska et al. 
2015). The effect of premenopausal LNG-IUS use on the risk of PFTC is not 
known. 
Symptoms of PFTC are nonspecific and mostly similar to those in ovarian 
cancer. However, PFTC is usually diagnosed at an earlier stage than ovarian 
cancer, as PFTC results in tubal distention and associated abdominal pain, as 
well as bloody-watery discharge (Horng et al. 2014). Due to the rarity of PFTC, 
optimal management of PFTC is still uncertain, and survival following PFTC 






Cervical cancer is the fourth most common female cancer worldwide with 
527 600 new cervical cancers in 2012 (Ferlay et al. 2012). Globally, large 
variations in the incidence of cervical cancer exist due to differences in human 
papilloma virus (HPV) prevalence, and striking disparities in the availability 
of protective vaccination against cervical cancer and screening programs 
(Torre et al. 2017). Approximately 85% of cervical cancers are diagnosed in 
low- or middle-income countries (Ferlay et al. 2015). In 2014, a total of 175 
new cervical cancers were diagnosed in Finland. The overall incidence of 
cervical cancer in Finland in 2014 was 4.7/100 000 women-years, adjusted for 
age of world standard population (www.cancerregistry.fi) (Figure 4). 
Other cancers 
 
Cancers of the colon and rectum (colorectal) are the second most common 
female cancer worldwide with 614 300 new cases annually in 2012 (Ferlay et 
al. 2012). There is substantial variation in incidence globally, with the highest 
rates occurring in high-income countries (Ferlay et al. 2012). In 2014, a total 
of 989 colon cancers and 428 rectosigmoid cancers were diagnosed among 
women in Finland (www.cancerregistry.fi). 
Globally, lung cancer is the third most common cancer among women, with 
583 100 new cases in 2012 (Ferlay et al. 2012). Lung cancer is one of the most 
preventable cancers, as smoking is the most important risk factor. Also, air 
pollutants have a significant role in the carcinogenesis of lung cancer (Torre et 
al. 2015). In Finland, a total of 937 lung cancers were diagnosed among 
Finnish women in 2014. In 2014, the incidence of lung cancer was 
13.3/100 000 women-years, adjusted for age of world standard population 
(www.cancerregistry.fi). 
In the same year, a total of 601 pancreatic cancers were diagnosed among 
women in Finland (www.cancerregistry.fi) and the incidence of pancreatic 




of world standard population (www.cancerregistry.fi). Pancreatic cancer is 
one of the deadliest cancers (Ilic and Ilic 2016), and the risk faced by women 
in Finland of dying from pancreatic cancer is third highest in the world (Ferlay 
et al. 2012, Ilic and Ilic 2016). The 5-year survival was 8% among women 
during 2010–2014 in Finland (Engholm et al. 2016). Tobacco smoking is a 
known risk factor for pancreatic cancer, and also certain other risk factors 
(e.g., obesity, alcohol, and diabetes) have been identified, but the causes of this 





Treatment of heavy menstrual bleeding, and cancer risk 
Hormonal aspects of carcinogenesis – the role of progestogens 
 
In addition to the actions of estrogen and progestogens in the normal 
physiology of reproductive organs, they have an impact on carcinogenesis. 
Estrogen acts via ER-α and ER-β, and progestogens via two PRs – PR-A and 
PR-B – existing in mammary glands, the female reproductive tract (Chuffa et 
al. 2017), and in other tissues such as in the pancreas (Robles-Diaz and 
Duarte-Rojo 2001), lung (Siegfried and Stabile 2014), and colon (Singh et al. 
1993). Imbalances in the actions of sex hormones as well as the altered 
function of sex hormone receptors in female organs are associated with 
various diseases such as AUB, and cancers of reproductive organs (Diep et al. 
2015, Maybin and Critchley 2015, Chuffa et al. 2017). An excessive estrogen 
effect in the endometrium without effective progestogen action increases the 
risk of endometrial carcinogenesis (Kamal et al. 2016). Likewise in the 
endometrium, progestogens have protective effects on ovaries by decreasing 
the proliferative effects of estrogen, by suppressing ovulations (Ivarsson et al. 
2001, Chuffa et al. 2017), and by inducing cell differentiation and apoptosis in 
ovarian cells (Bu et al. 1997, Diep et al. 2015, Chuffa et al. 2017). In contrast to 
their effect on the uterus and ovaries, progestogens can have a proliferative 
effect on the mammary gland (Aupperlee et al. 2005, Garcia y Narvaiza et al. 
2008). 
All hormonal treatments for HMB are based on progestins and their actions 
on the endometrium. Progestins used in the medical treatment of HMB vary 
significantly. Synthetic progestins can be structurally related either to 
progesterone or testosterone (e.g., levonorgestrel) and their binding affinity to 
hormone receptors varies (Carp 2015) (Table 2). The pharmacological 
differences of progestins may explain their various actions depending on the 
tissue. Also, the delivery mode (per oral, parenteral), continuity of 
administration (cyclic, continuous), metabolism, and hormonal milieu in the 





All progestogens mediate their actions by binding to the PRs in the cellular 
nucleus and activate PR signaling pathways, leading to changes in gene 
transcription and protein expression in the target cell. In mammary tissue, the 
proliferative effect of progestogens is mediated on both PR-positive and PR-
negative breast cells. Progestogens directly bind to and stimulate PR-positive 
breast cells to produce and secrete cytokines and growth factors (e.g., receptor 
activator of nuclear factor κB ligand, and Wnt) which have a proliferative effect 
on adjacent PR-negative mammary cells (paracrine signaling) (Diep et al. 
2015). It has been proposed that the increased breast cancer risk during 
postmenopausal HT is caused not only by direct proliferative effect of 
progestin on PR-positive precursor lesions, but also by expansion of PR-
negative mammary stem/progenitor cells (Joshi et al. 2010, Asselin-Labat et 
al. 2010). 
In addition, the actions of progestogens are mediated via androgen receptors, 
glucocorticoid receptors, and mineralocorticoid receptors but the binding 
affinities of different progestogens vary significantly (Stanczyk et al. 2013) 
(Table 2). Compared with other progestins, levonorgestrel has a high affinity 
for PR, relatively high affinity to androgen receptors, and a high bioavailability 














Table 2. The binding affinities of different progestogens to various steroid hormone receptors. 
Modified from the review by Schindler A.E. in the textbook Progestogens in Obstetrics and 
Gynecology, ed. Carp, H.J.A. 2015. 
Progestogen PR AR ER GR MR SHBG CBG Albumin bound Free 
Progesterone 50 0 0 10 100 0 36 79.3 2.4 
Dydrogesterone 75 0 ND ND ND ND    
Cyproterone acetate 90 6 0 6 8 0 0   
Medroxyprogesterone acetate 115 5 0 29 160 0 0   
Megestrol acetate 65 5 0 30 0 0 0   
Nomegestrol 125 6 0 6 0 0 0   
Promegestone 100 0 0 5 53 0 0   
Drospirenone 35 65 0 6 230 0 0   
Norethisterone 75 15 0 0 0 16 0 60.8 3.7 
Levonorgestrel 150 45 0 1 75 50 0 50.0 2.5 
Norgestimate 15 0 0 1 0 0 0   
Desogestrel (etonogestrel) 150 20 0 14 0 15 0 65.5 2.5 
Gestodene 90 85 0 27 290 40 0 24.1 0.6 
Dienogest 5 10 0 1 0 0 0   
          
AR = androgen receptor (metribolone = 100%), CBG = corticosteroid-binding globulin 
(cortisol = 100%), ER = estrogen receptor (estradiol-17β = 100%), GR = glucocorticoid receptor 
(dexamethasone = 100%), MR = mineralocorticoid receptor (aldosterone = 100%), ND = not 
determined, PR = progesterone receptor (promegestone = 100%), SHBG = sex hormone binding 
globulin (dihydrotestosterone = 100%). 
Hormonal treatment of heavy menstrual bleeding, and cancer risk 
Combined oral contraceptives 
 
Breast cancer 
A large meta-analysis of 54 studies defined the association between COCs and 
breast cancer (CGHFBC 1996). In this meta-analysis, the risk of breast cancer 
in current users of COCs was 24% higher than in never-users (Table 3). The 
finding of elevated breast cancer risk among COC users was later confirmed by 
many studies (Kumle et al. 2002, Marchbanks et al. 2002, Kahlenborn et al. 
2006, Hunter et al. 2010, Gierisch et al. 2013) (Table 3). However, in some 
studies only a slight increase or no increase in breast cancer risk has been 
reported (Hankinson et al. 1997, Hannaford et al. 2007, Vessey and Painter 
2006, Vessey and Yeates 2013, Iversen et al. 2017) (Table 3). Based on the 




breast cancer risk, the International Agency for Research on Cancer (IARC) 
has classified COCs as a carcinogenic agent (IARC 2012). In a recent meta-
analysis (Gierisch et al. 2013), the risk of breast cancer among ever-users of 
COCs was elevated by 8% compared with never-users (odds ratio [OR] 1.08, 
95% CI 1.00–1.17). However, the excess in breast cancer risk may be transient 
as the risk seems to disappear after 10 or more years since cessation of COC 
use (CGHFBC 1996, Urban et al. 2012, Iversen et al. 2017). 
The progestin component of COCs varies and may have an impact on cancer 
risk but only a few studies have provided information on specific formulations. 
In the Nurses’ Health Study II (Hunter et al. 2010), a tri-phasic preparation 
with levonorgestrel was associated with an increased risk of breast cancer (RR 
3.05, 95% CI 2.00–4.66). In the Women’s Care Study (Marchbanks et al. 
2002, Marchbanks et al. 2012), no increase in risk was observed for 
levonorgestrel-containing preparations but the number of women was sparse. 
To evaluate possible carcinogenic effects of different progestins in COCs, more 




















Table 3. Studies on combined oral contraceptive use and risk of breast cancer. 
Study Study design, 





RR/OR/HR (95% confidence 
interval) 
Oxford (CGHFBC 1996) Meta-analysis 
53 297/100 239 
1976–1992 1.24 (1.15–1.33) 
current/recent use 
1.16 (1.08–1.23) 1–4 y since 
last use 
1.07 (1.02–1.13) 5–9 y since 
last use 
1.01 (0.96–1.05) > 10 y since 
last use 
The Nurses’ Health Study I 
(Hankinson et al. 1997) 
Cohort 
3 383 
1976–1992 1.11 (0.94–1.32) 
0.96 (0.65–1.43) > 5 y use  
Women’s Care (Marchbanks et al. 
2002) 
Cohort 
4 575/4 682 
1994–1998 1.0 (0.8–1.1) 
1.3 (1.0–1.7) premenopausal 
breast cancer 
Women’s Lifestyle and Health Study 
(Kumle et al. 2002) 
Cohort 
103 027 
1991–1999 1.2 (1.1–1.4) former users 
1.6 (1.2–2.0) current/recent 
users 
Oxford Family Planning Association 




1968–1974 1.0 (0.8–1.1), follow-up until 
end of 2004 
1.0 (0.9–1.1), follow-up until 
end of 2010 
Mayo Clinic (Kahlenborn et al. 2006) Meta-analysis 
 
1980–2004 1.19 (1.09–1.29) ever-users 
RCGP (Hannaford et al. 2007, Iversen 
et al. 2017) 
Cohort 
46 000 
1968–1969 0.98 (0.87–1.19), follow-up 
until end of 2004 
1.04 (0.91–1.17), follow-up 
until end of 2012  
The Nurses’ Health Study II (Hunter 
et al. 2010) 
Cohort 
116 413 
1989–2001 1.12 (0.95–1.33) past use 
1.33 (1.03–1.73) current use 
1.16 (0.80–1.69) 0–8 y use 
1.42 (1.05–1.94) > 8 y use  
Johannesburg Cancer Case-Control 
Study (Urban et al. 2012) 
Case-control 
1 664/1 492 
1995–2006 1.66 (1.28–2.16) all 
current/recent users vs 
never-users 
1.57 (1.03–2.40) only oral 
contraceptive users 
1.11 (0.91–1.36) > 10 y since 
last use 
The Agency for Healthcare Research 
and Quality Evidence Report (Gierisch 
et al. 2013) 
Meta-analysis 
317 341 
2000–2012 1.08 (1.00–1.17) ever-users 
vs never-users 
1.21 (1.04–1.41) 0–5 y since 
last use 
1.17 (0.98–1.38) 5–10 y since 
last use 
1.13 (0.97–1.31) 10–20 y 
since last use 
1.02 (0.88–1.18) > 20 y since 
last use 







A decreased risk of endometrial cancer among COC users has been widely 
reported (Weiss and Sayvetz 1980, Schlesselman 1997, Vessey and Painter 
2006, Hannaford et al. 2007, Dossus et al. 2010, Iversen et al. 2017). 
According to a recent meta-analysis (Gierisch et al. 2013), the risk of 
endometrial cancer among ever-users of COC was estimated to be 
approximately halved compared with non-users (OR 0.57, 95% CI 0.43–0.77). 
The protective effect of COCs against endometrial cancer has been reported to 
persist over 20 years (Schlesselman 1997, Iversen et al. 2017). Based on robust 
data, IARC has concluded that COCs are a protective agent against 
endometrial cancer (IARC 2012). 
 
Ovarian cancer 
There is consistent evidence from numerous studies that COCs are associated 
with significantly decreased risk of ovarian cancer (IARC 2012, Havrilesky et 
al. 2013) and the risk reduction is positively associated with the length of COC 
use. The risk is more than halved after 10 years of COC use and the protective 
effect seems to persist for decades (Collaborative Group on Epidemiological 
Studies of Ovarian Cancer 2008, Havrilesky et al. 2013). The protective effect 
of COCs against ovarian cancer is plausible via many proposed mechanisms. 
COCs suppress ovulations which cause microtrauma in the ovarian epithelium 
and is one of the proposed mechanisms of ovarian carcinogenesis (Fathalla 
1972). With decreased ovulations, the exposure of the epithelium of the 
fallopian tube to carcinogenic agents in follicular fluid or other 
microenvironmental changes during ovulations is decreased (Crum et al. 
2007). 
 
Primary fallopian tube carcinoma 
PFTC is a rare cancer whose etiology is not well known. Hormonal factors may 
play a role as oral contraceptive use has been associated with decreased risk of 






The development of cervical cancer is caused by persistent high-risk HPV 
infection (Bosch et al. 2002, Cogliano et al. 2005) but co-factors such as sex 
hormones and Chlamydia trachomatis infection also may have a role in the 
cervical malignant transformation in HPV-positive women (Paavonen et al. 
1979, Munoz et al. 2002, Luostarinen et al. 2004, Brake and Lambert 2005, 
Ramachandran 2017). Current and long-term COC use is a risk factor for 
cervical cancer among HPV-positive women (Moreno et al. 2002, Smith et al. 
2003, International Collaboration of Epidemiological Studies of Cervical 
Cancer et al. 2007, Gierisch et al. 2013) but the elevated risk declines 10 years 
after cessation of COC use (International Collaboration of Epidemiological 
Studies of Cervical Cancer et al. 2007). However, the true effect of COCs on 
carcinogenesis may be difficult to assess as women using COCs for longer 
times may have increased sexual activity and thus more significant HPV 




The use of COCs has been associated with a decreased risk of colorectal cancer 
in numerous studies (Nichols et al. 2005, Bosetti et al. 2009, Gierisch et al. 
2013, Iversen et al. 2017). The reported reductions in risk vary between 
approximately 15% and 20% for ever- versus never-users of COCs respectively 
(Bosetti et al. 2009, Gierisch et al. 2013), and the protective effect is stronger 
among current users of COCs (Nichols et al. 2005, Bosetti et al. 2009, Cibula 




At the time of planning this thesis, only one study had been published on LNG-




2005). During our work, two other studies were published (Dinger et al. 2011, 
Heikkinen et al. 2016a) (Table 4). 
Backman et al. conducted a post-marketing cohort study with 17 360 women 
(mean age 35.4 years) using LNG-IUS for contraception in Finland (Backman 
et al. 2005). In that study, the incidence of breast cancers during 1990–2000 
among the LNG-IUS users in each 5-year group of LNG-IUS users was 
compared with the corresponding breast cancer incidence in the Finnish 
general population in 1998. The incidence of breast cancer was non-
significantly higher among LNG-IUS users aged 30–39 years compared with 
the background population. Also, in other age groups, no significant 
associations were observed (Table 4). 
In a case-control study from Finland and Germany by Dinger et al. (2011), 
prior use of copper intrauterine device (IUD) or LNG-IUS was compared 
between 5 113 women with breast cancer diagnosed before age 50, and 20 452 
healthy controls. The use of LNG-IUS was self-reported and cancer diagnoses 
were obtained from cancer registries. Ever- or current use of LNG-IUS was not 
associated with increased risk of breast cancer compared with copper IUD use 
(Table 4). 
In the case-control study by Heikkinen et al. (2016a), 5 927 women with breast 
cancer diagnosed at ages 22–60 years during 2000–2007, and 19 633 healthy 
controls were studied. Information on LNG-IUS use and potential 
confounders (e.g., use of hormonal contraception or HT, family history of 
cancer, alcohol use, body mass index) were obtained via a survey. Among 
women aged 25–50 years with exclusive use of LNG-IUS, no risk of breast 
cancer was observed compared with never-users. In women over 50, the risk 
of breast cancer was increased (Table 4). Also, a prior study reported an 
increased risk of breast cancer among postmenopausal women (Lyytinen et al. 








Table 4. Studies on use of the levonorgestrel-releasing intrauterine system and breast cancer 
risk. 







Country Age (years) RR/OR/HR (95% 
confidence interval) 




30–54 y (mean 
35.4) 
1990–2000 
1990–1993 Finland 30–54  Breast cancer 
incidences  





30–34 y: 27.2 vs 25.5 
35–39 y: 74.0 vs 49.2 
40–44 y: 120.3 vs 
122.4 
45–49 y: 203.6 vs 
232.5 
50–54 y: 258.5 vs 
272.6 





1995–2007 Finland 50–62 Estradiol+LNG-IUS:  
2.07 (1.78–2.41); 




329 cases and 708 
controls 








< 50 y 0.99 (0.88–1.12) 
ever-use of LNG-IUS 
vs ever-use of 
copper IUD 
0.85 (0.52–1.39) 
current use of LNG-
IUS vs current use of 
copper IUD  





2000–2007 Finland 22–60 y 25-50 y: 1.00 (0.77–
1.30); 75 cases and 
261 controls 
51–64 y: 1.63 (1.26–
2.11); 73 cases and 
137 controls 
HR = hazard ratio, IUD = intrauterine device, LNG-IUS = levonorgestrel-releasing intrauterine system, 
OR = odds ratio, RR = relative risk. 
 
Endometrial cancer 
At the initiation of our study, nothing was known about the effect of LNG-IUS 




this thesis. Our hypothesis of the protective effect of LNG-IUS against 
endometrial carcinogenesis was based on the findings of the antiproliferative 
effect of progestins in the endometrium, the powerful effect of LNG-IUS 
against endometrial proliferation (Andersson and Rybo 1990, Mansour 2012), 
and the studies of decreased endometrial cancer risk among non-hormonal 
IUD users (Felix et al. 2015). LNG-IUS has also been reported to be an effective 
treatment for endometrial hyperplasia, a potential precursor of endometrial 
cancer (Gallos et al. 2013, Yuk et al. 2016). 
During our work, a Finnish register-based case-control study reported a 
decreased risk of endometrial cancer among postmenopausal women using 
LNG-IUS combined with ET (OR 0.34, 95% CI 0.16–0.72) or alone (OR 0.27, 
95% CI 0.13–0.56) (Jaakkola et al. 2011), but the number of LNG-IUS users 
was low in that study. 
 
Ovarian cancer 
During the planning of our study, no reports on LNG-IUS use and ovarian 
cancer existed. During our work, a Finnish register-based case-control study 
(Koskela-Niska et al. 2013b) among postmenopausal women reported no 
increase in risk of ovarian cancer among women using ET with LNG-IUS (23 
cases, 64 controls; OR 1.02, 95% CI 0.63–1.66). 
 
Primary fallopian tube carcinoma 
At the initiation of this study, no reports on LNG-IUS and PFTC risk existed. 
During the study, Koskela-Niska et al. reported an increased risk of PFTC 
among postmenopausal women with HT, also in the form of LNG-IUS 
(Koskela-Niska et al. 2015). 
 
Cervical cancer 
According to a pooled analysis of 26 epidemiological studies, ever-use of IUD 
was associated with a halved risk of cervical cancer (Castellsague et al. 2011). 
A study from Brazil with 187 LNG-IUS users and follow-up for 7 years 




(Lessard et al. 2008). However, the incidence of cervical cancer among LNG-
IUS users is unknown. 
Oral progestins 
 
Progestins, especially norethisterone acetate, are used for HMB, but no reports 
on exclusive use of oral progestin for HMB and cancer risk exist. The only 
report on premenopausal use of non-contraceptive oral progestins and cancer 
risk is on breast cancer risk. 
A prospective French E3N cohort study (Fabre et al. 2007) among over 73 000 
women aged 40–64 years (mean 51.8 years) and mean follow-up of 9.1 years 
found no significant association between premenopausal ever-use of oral 
progestin and risk of breast cancer compared with never-users (RR 1.01, 95% 
CI 0.93–1.11). However, for progestin use of over 4.5 years, an increase in 
breast cancer risk was observed (RR 1.44, 95% CI 1.03–2.00). Compared with 
never-users, each additional year of progestin use increased the risk of breast 
cancer by 3%, and after discontinuation of use, the risk decreased to baseline 
(Fabre et al. 2007). A limitation was that information on the indications or the 
dosages of progestins was not provided. 
Surgical treatment of heavy menstrual bleeding, and cancer risk 
Hysterectomy and cancer risk 
 
Breast cancer 
Hysterectomy reduces HMB by 100% but surgical removal of the uterus has 
been reported to affect the circulation of blood in the ovaries, resulting in 
damage to ovarian function. This leads to a decrease in endogenous lifetime 
sex hormone exposure, which could predispose to later health outcomes such 
as cardiovascular disease and cancer (Judd et al. 1974, Farquhar et al. 2005, 
Xiangying et al. 2006). In a study among 66 802 postmenopausal women 




45 years was associated with a reduced risk of breast cancer (OR 0.80, 95% CI 
0.69–0.94). Similar findings have been reported by others (Press et al. 2011). 
The impact on cancer risk seems to be more pronounced when hysterectomy 
is performed together with a bilateral salpingo-oophorectomy (BSO). In the 
Nurses’ Health Study (Parker et al. 2009), the risk of breast cancer after 
hysterectomy with BSO was reduced by 25% at all ages (RR 0.75, 95% CI 0.68–
0.84), but the decrease was largest among women under 45 years (RR 0.62, 
95% CI 0.53–0.74) compared with those with simple hysterectomy. Similar 
findings on breast cancer risk have been reported by other studies (Gaudet et 
al. 2014), but not all (Jacoby et al. 2011). Simple bilateral oophorectomy at age 
under 45 years has been reported to decrease breast cancer risk by 
approximately 50% (Schairer et al. 1997, Press et al. 2011) and the protective 
effect is evident for 10 years after surgery (Schairer et al. 1997). 
 
Ovarian cancer 
The effect of hysterectomy on the risk of ovarian cancer is unclear. No effect 
was seen for ovarian cancer risk at any ages in the study by Gaudet et al. 
(2014). In contrast, an Italian case-control study reported a decreased risk of 
ovarian cancer (1 031 cases, 2 411 controls; OR 0.6, 95% CI 0.4–0.9) among 
women with previous hysterectomy (Chiaffarino et al. 2005). 
 
Other cancers 
The effect of hysterectomy on other cancers has been studied less. In the study 
by Gaudet et al. (2014), no effect on the risks of colorectal cancer, lung cancer, 
non-Hodgkin lymphoma, or kidney cancer was observed. However, simple 
hysterectomy was associated with an increased risk of pancreatic cancer (RR 
1.48, 95% CI 1.03–2.14). 
Endometrial ablation and cancer risk 
 
In endometrial ablation, the endometrium is deeply destroyed, but some 
endometrial islands may remain. Whether the ablation affects later risk of 




Cooper et al. 2011, Dood et al. 2014, Singh et al. 2016). Most studies have 
reported no significant impact on endometrial cancer risk (Krogh et al. 2009, 
Cooper et al. 2011, Dood et al. 2014), but one study observed a decreased risk 
of endometrial cancer after endometrial ablation (Singh et al. 2016) (Table 5). 
The incidence of breast cancer among women treated with endometrial 
ablation is unclear, although one previous study has reported a 1.15% 
incidence of breast cancer among endometrial ablation treated women 
(Cooper et al. 2011) (Table 5). 
Table 5. Studies on endometrial ablation and cancer risk. 
Study Study design, size of 
cohort/cases/controls, age, 








Krogh et al. 2009 Cohort 
n = 367 (421 TRCEs) 








incidence 3/367  
Cooper et al. 2011 Cohort, population-based 

















Dood et al. 2014 Cohort 
n = 4776 













Singh et al. 2016 Cohort 
n = 1 521 
48 ± 6.3 y 
1022 (67.19%) 1st generation EA, 










RR 0.0135 (95% 
CI 0.0007–
0.2801), 
p = 0.0054 
    






This thesis was designed to assess the cancer risks after intrauterine treatment 
(LNG-IUS or endometrial ablation) for HMB. In particular, the risks of 
endometrial cancer and breast cancer were the focus of interest. Secondly, we 
wanted to evaluate the need for hysterectomy among women treated with 
endometrial ablation. All studies were register-based nationwide cohort 
studies. 
 
The specific objectives of the study were: 
 
1. To evaluate the overall cancer risk, with a special interest in 
endometrial cancer and breast cancer among LNG-IUS users 
(Study I). 
 
2. To assess the risk of most common breast cancer subtypes among 
LNG-IUS users (Study II). 
 
3. To elucidate the impact of LNG-IUS use on different histological 
subtypes of ovarian cancer and on the risk of PFTC (Study III). 
 
4. To study the risk of endometrial cancer, other gynecological cancers, 




Subjects and methods 
Permissions 
This study was performed with permission from the Finnish National Centre 
for Welfare and Health (1881/5.05.00/2010; 1165/5.05.00/2016; 
880/5.05.00/2016). 
Registers used 
In Finland, there exist many administrative and health registers which collect 
nationwide data on health-related information and are mandated by law. This 
national policy makes these registers very reliable, with information coverage 
of almost 100%, thus enabling register-based studies. The unique personal 
identity code issued by the Finnish Population Register Centre to all Finnish 
citizens and permanent residents since 1967 is used as an identification key in 
all these national health registers and is used for data linkages between the 
registers. 
The data on LNG-IUS reimbursements (Mirena®, Bayer Oy, Turku, Finland) 
for treatment of HMB were obtained from the national Medical 
Reimbursement Register of the Social Insurance Institution, which contains 
data on LNG-IUS purchases in electronic form since 1994. 
The information on cancer diagnoses among study subjects and nationwide 
cancer incidence (Studies I–IV) was received from the Finnish Cancer 
Registry. Since 1961, reporting of new cancer cases has been mandatory by law 
in Finland. The Finnish Cancer Registry covers virtually 100% of diagnosed 
cancers in Finland since 1953 (Teppo et al. 1994). 
The data on gynecological surgical operations (endometrial ablations, 
hysterectomies, oophorectomies, salpingectomies, etc.) were obtained from 




and Welfare (Studies I–IV). The coverage of this register is nearly 100% 
(Keskimäki and Aro 1991). 
Sterilization data (Study IV) were received from the Sterilization Register of 
the Finnish National Institute for Health and Welfare. 
The data on deliveries of live babies of both the study subjects and of the 
control cohort (Study IV) were obtained from the Finnish Population Register 
Centre. The information on the mode of deliveries (i.e., vaginal deliveries, 
cesarean sections) during 1987–2015 were received from the Birth Register of 
the Finnish National Institute for Health and Welfare. 
The information on emigration dates and death dates was obtained from the 
Finnish Population Register Centre. 
In Study I, additional data of self-reported cancer-related confounders (i.e., 
alcohol consumption, smoking, physical activity, diet, and socioeconomic 
status) were derived from a series of cross-sectional national health behavior 
surveys (the Health Behavior and Health among the Finnish Adult Population 
Survey [AVTK]). AVTK is a nationwide survey conducted by the National 
Institute for Health and Welfare. In the AVTK, a nationwide random sample 
from the Finnish Population Register aged 15–64 years was drawn annually 
during 1978–2002 with some 5000 Finnish people receiving a mailed 
questionnaire each year. The response rate among women varied between 75% 
and 86% (Tolonen et al. 2006). The data from women aged 30–49 years who 
returned the questionnaire were analyzed (n = 4056 LNG-IUS users; 
n = 25 801 non-users). 










Table 6. Registers used in Studies I–IV. 











1994– I, II, III 
Finnish Cancer Registry Cancer diagnoses, 
clinical stage of 
cancer at diagnosis, 
and cancer deaths  
1953– I, II, III, IV 
Hospital Discharge Register 




1987– I, II, III, IV 
Sterilization Register 






(National Institute for Health 
and Welfare) 
Dates of deliveries, 
modes of deliveries 
1987– IV 
Finnish Population Register 
(Finnish Population Register 
Centre) 
Date of emigration, 
date of death 
1972– I, II, III, IV 
Dates of deliveries of 
live babies 
1972– IV 
LNG-IUS = levonorgestrel-releasing intrauterine system 
Study populations 
For the studies of LNG-IUS users and cancer risk (Studies I–III), we identified 
from the Medical Reimbursement Register of the Social Insurance Institution 
of Finland all Finnish women who had received reimbursement for LNG-IUS 
for HMB at ages 30–49 years during 1994–2007 (n = 93 843). 
In the study of endometrial ablation (Study IV), we identified all Finnish 
women who in 1997–2014 had undergone endometrial ablation at age 30–
49 years. These women were extracted from the Hospital Discharge Register 
of the Finnish National Institute for Health and Welfare by using NOMESCO 




endometrium). For each endometrial ablation case, five control women born 
at the same time (± 6 months), living in the same area, and alive at the index 
date (date of endometrial ablation) were randomly selected from the Finnish 
Population Register. Endometrial ablation cases and controls with previous 
cancer diagnosis before the index date were excluded. The final endometrial 
ablation cohort included 5 484 women, and the control cohort 26 938 women 
(Figure 8). 
Figure 8. Flow chart of women included in Study IV concerning 
endometrial ablation and cancer risk. 
Women with 
endometrial ablation 


























Controls of those endometrial 
ablation cases with discrepancies 
in diagnoses
N=10
Controls of those endometrial 






In Study IV, most women had had two prior deliveries before the index date; 
38.0% in the endometrial ablation cohort, and 36.9% in the control cohort. 







Table 7. Baseline characteristics of all Finnish women treated with endometrial ablation in 1997-
2014 at ages 30-49 years, and their control group at the beginning of the follow-up.  
 
Patient charasteristic Endometrial 
ablation  
Controls  p 
Number of women 5 484 26 938  
Age at the beginning of 
follow-up, years    
30-34 329 (6.0%) 1 624 (6.0%) 0.955 
35-39 1 286 (23.5%) 6 364 (23.6%) 0.789 
40-44 2 152 (39.2%) 10 569 (39.2%) 1.000 
45-49 1 718 (31.3%) 8 381 (31.1%) 0.772 
Parity     
0 282 (5.1%) 4 370 (16.2%) <0.0001 
1 575 (10.5%) 4 373 (16.2%) <0.0001 
2 2 082 (38.0%) 9 951 (36.9%) 0.160 
3 1 629 (29.7%) 5 557 (20.6%) <0.0001 




The standardized incidence ratios (SIRs) were calculated by dividing the 
observed cancer cases by the numbers expected. The expected number of 
cancers was calculated by multiplying the number of women-years in each 5-
year age group and calendar period by the corresponding cancer incidence 
among all Finnish women for each primary cancer site. Ninety-five percent CIs 
were based on the assumption that the number of observed cases represents a 
Poisson distribution (Rothman et al. 2008). 
In Studies I–III, the women-years at risk were calculated starting from the 
date of the first purchase of LNG-IUS and ending on the study closing date, 
the 55th birthday, hysterectomy, bilateral/unilateral salpingectomy, salpingo-
oophorectomy or oophorectomy, or on emigration, or death, whichever 
occurred first. In Study IV, the follow-up started from the index date, and 
ended at the end of 2014, on emigration, or death, whichever occurred first. In 
Study IV, censoring at the date of hysterectomy in the analyses for uterine 




oophorectomy, or oophorectomy in the analyses for ovarian cancer risk was 
done. The study closing dates were at the end of 2009 (Study I), the end of 
2012 (Study II), the end of 2013 (Study III), or at the end of 2014 (Study IV). 
In Study I, multivariate logistic regression models were used to assess, by 
means of ORs with 95% CIs, the association between individual behavior 
factors and the use of LNG-IUS. 
In Study IV, a multivariate Poisson regression model by means of hazard 
ratios (HRs) with 95% CIs with women-years as offset was used to evaluate the 
risk factors for hysterectomy after endometrial ablation. The age of a woman 
at endometrial ablation, parity, number of cesarean sections, sterilization, and 
the follow-up time were included in the final model. We used a cause-specific 
hazard method (Putter et al. 2007) where death was used as a competing event 





The main results are presented here, and further data are shown in the original 
publications. 
 
Cancer risk among LNG-IUS users 
Breast cancer (Study I, II) 
 
During the study period, a total of 93 843 LNG-IUS users were followed for 
855 324 women-years in Study I, and for 1 032 767 women-years in Study II 
(Table 8). 
 
Table 8. Cohorts of levonorgestrel-releasing intrauterine system (LNG-IUS) users (n) in 
Studies I–II. Follow-up started from the first or second purchase of LNG-IUS. 
 Follow-up from the first LNG-IUS Follow-up from the second LNG-IUS 









30–34 20 998 47 196 47 196 290 365 365 
35–39 28 220 168 763 172 523 4 151 10 335 10 352 
40–44 25 954 250 431 285 032 5 643 33 547 35 218 
45–49 18 671 240 504 310 402 4 150 40 962 52 677 
50–54 0 148 430 217 615 0 23 211 38 305 
Total 93 843 855 324 1 032 767 14 234 108 420 136 917 
       
n = number of all women counted by age at the purchase of LNG-IUS; women-years counted 
by age at the follow-up; cancer cases counted by age at diagnosis. 
¹ Follow-up 1994–2009. 
² Follow-up 1994–2012. 
 
In Study I, a total of 2 781 cancers were diagnosed during the study period. 
The overall cancer incidence was 7% higher among LNG-IUS users than 




cancers among LNG-IUS users, 1 542 were breast cancers (250 breast cancer 
cases more than expected). The risk of breast cancer among all LNG-IUS users 
was 19% higher than in the background population (SIR 1.19, 95% CI 1.13–
1.25). Of the 93 843 LNG-IUS users, 14 234 had two or more LNG-IUS 
purchases. Among the women with two or more LNG-IUS purchases, the SIR 
for breast cancer was 1.40 (95% CI 1.24–1.57) (Table 9). 
Table 9. Observed number of cancer cases (OBS) and standardized incidence ratios (SIRs), with 
95% confidence interval (CI), among Finnish women with levonorgestrel-releasing intrauterine 
system (LNG-IUS) purchase at ages 30–49 years, by type of cancer and number of LNG-IUS 
purchases. Follow-up 1994–2009. 
  ≥ 1 purchase of LNG-IUS¹ ≥ 2 purchases of LNG-IUS² 
Cancer type  OBS SIR 95% CI OBS SIR 95% CI 
All sites 2781 1.07 1.03–1.11*** 454 1.20 1.09–1.31*** 
Stomach 45 1.10 0.80–1.47 7 1.22 0.49–2.51 
Colon and rectum 154 1.17 0.99–1.36 24 1.22 0.78–1.81 
Liver 6 0.69 0.25–1.50 2 1.58 0.19–5.69 
Gallbladder, bile ducts 7 0.88 0.35–1.81 2 1.77 0.21–6.37 
Pancreas 15 0.50 0.28–0.81** 3 0.66 0.14–1.91 
Lung, trachea 43 0.68 0.49–0.91** 3 0.31 0.06–0.91* 
Melanoma of skin 129 1.08 0.90–1.27 19 1.11 0.67–1.73 
Breast 1542 1.19 1.13–1.25*** 271 1.40 1.24–1.57*** 
Cervix uteri 60 0.90 0.69–1.15 6 0.76 0.28–1.65 
Adenocarcinoma of  
cervix uteri 22 1.18 0.74–1.79 2 0.91 0.11–3.30 
Vulva 8 0.81 0.35–1.59 3 2.13 0.44–6.21 
Vagina 4 1.32 0.36–3.38 0 0.00 0.00–7.40 
Corpus uteri (all types) 56 0.59 0.45–0.77*** 5 0.36 0.12–0.83* 
   Endometrial 
adenocarcinoma  37 0.46 0.33–0.64*** 3 0.25 0.05–0.73** 
Uterine sarcomas 18 1.44 0.86–2.28 2 1.17 0.14–4.22 
Other uterine 0 0.00 0.00–3.27 0 0.00 0.00–35.65 
Ovary, all types 59 0.60 0.45–0.76*** 7 0.51 0.20–1.04 
Kidney 40 0.98 0.70–1.32 10 1.63 0.78–3.00 
Bladder, ureter, urethra 12 0.98 0.51–1.70 3 1.75 0.36–5.10 
Brain, nervous system 175 1.04 0.89–1.19 25 1.07 0.69–1.57 
Thyroid gland 138 1.09 0.92–1.28 21 1.25 0.77–1.90 
Non-Hodgkin lymphoma 81 1.07 0.85–1.32 10 0.91 0.44–1.67 
Hodgkin lymphoma 13 1.19 0.63–2.03 2 1.77 0.21–6.41 
Multiple myeloma 11 0.94 0.47–1.68 2 1.19 0.14–4.29 
Leukaemia 34 0.93 0.64–1.29 2 0.38 0.05–1.37 
* p < 0.05; ** p < 0.01; *** p < 0.001 
¹Follow-up from the first purchase of LNG-IUS. 
²Follow-up from the second purchase of LNG-IUS. 





In Study II, a total of 2015 breast cancers were diagnosed among LNG-IUS 
users during the follow-up of over one million women-years. The mean follow-
up was 11.0 years (maximum 19 years). Of the 2015 breast cancers, 1598 
(79.3%) cases were invasive ductal cancers, 376 (18.7%) were invasive lobular 
cancers, and 41 (2%) had other histologies. The risks of both invasive lobular 
cancer (SIR 1.33, 95% CI 1.20–1.46) and ductal cancer (SIR 1.20, 95% CI 1.14–
1.25) were increased compared with those of the background population. 
Among women with two or more LNG-IUS purchases, the SIR for invasive 
lobular cancer was 1.73 (95% CI 1.37–2.15), and for invasive ductal cancer 1.37 
(95% CI 1.21–1.53).  
The SIRs for both invasive lobular and ductal cancer were not increased during 
the first years of follow-up, but a significant elevation in SIRs was noticed after 
5 years of follow-up (Figure 9). 
 
Figure 9. The standardized incidence ratios (SIRs) of invasive 
ductal and lobular breast cancers during the follow-up in 
Study II. Follow-up 1994–2012. LNG-IUS = levonorgestrel-
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The SIRs were slightly higher for localized breast cancer than for non-localized 
breast cancer among LNG-IUS users. After 5 years of follow-up, the risks of 
non-localized ductal and lobular cancers were statistically significantly higher 
among LNG-IUS users than in the general population (Figure 10). 
 
 
Figure 10. Standardized incidence ratios (SIRs) of localized 
and non-localized breast cancers among levonorgestrel-





In absolute numbers, 2-4 excess cases of breast cancers were observed among 
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Gynecological cancers (Study I, III) 
 
Endometrial cancer (Study I) 
 
A total of 37 endometrial cancers (endometrial adenocarcinoma) were 
diagnosed among LNG-IUS users during the follow-up of 855 324 women-
years in Study I (Table 9). LNG-IUS users had a significantly decreased risk of 
endometrial cancer compared with the general population (SIR 0.46, 95% CI 
0.33–0.64). In absolute numbers, this means 3-6 prevented endometrial 
cancers per 10 000 LNG-IUS users followed for 10 years. After two purchases 
of LNG-IUS, the SIR for endometrial cancer was 0.25 (95% CI 0.05–0.73). The 
decreased risk of endometrial cancer was seen already in the first years of 
follow-up and was maintained during the whole follow-up (Table 10). 
 
Table 10. Observed number of endometrial cancers (OBS) and standardized incidence ratios 
(SIRs), with 95% confidence interval (CI), among Finnish women with levonorgestrel-releasing 
intrauterine system (LNG-IUS) for heavy menstrual bleeding at ages 30–49 years during 1994–





Time since the first purchase of LNG-IUS 
0–0.99 years 1–4.99 years 5–9.99 years 10 years or over 
OBS SIR 95% CI OBS SIR 95% CI OBS SIR 95% CI OBS SIR 95% CI 
30–34 0 0.00 0.00–21.39 0 0.00 0.00–14.04       
35–39 0 0.00 0.00–5.49 1 0.45 0.01–2.47 1 1.36 0.03–7.58    
40–44 0 0.00 0.00–2.83 4 0.80 0.22–2.04 2 0.45 0.05–1.63 0 0.00 0.00–4.83 
45–49 2 0.87 0.11–3.14 5 0.51 0.17–1.18 4 0.41 0.11–1.04 1 0.30 0.01–1.68 
50–54 0 0.00 0.00–11.55 4 0.41 0.11–1.05 9 0.44 0.20–0.82** 4 0.49 0.13–1.26 
Total 2 0.42 0.05–1.51 14 0.52 0.28–0.86** 16 0.45 0.26–0.72*** 5 0.41 0.13–0.95* 
* p < 0.05 
** p < 0.01 
*** p < 0.001 
 
Ovarian cancer and primary fallopian tube carcinoma (Study I, 
III) 
 
In Study I, the SIR for ovarian cancer in general was 0.60 (95% CI 0.45–0.76; 
59 observed compared with 99 expected cases) (Table 9). In Study III, a total 




the follow-up of 1 083 126 women-years. The risk of ovarian cancer was 41% 
lower among LNG-IUS users compared with the general population (SIR 0.59 
(95% CI 0.47–0.73). Of the invasive ovarian cancers, 46 were serous, 11 
mucinous, 11 endometrioid, and 3 were clear cell carcinomas. The rest were 
other less common types (Table 11). 
Of the epithelial ovarian cancers, the RR was lowest for mucinous carcinoma 
and highest for serous carcinoma among LNG-IUS users (Table 11. The 
decreased incidence of invasive ovarian cancers was seen during the first 
5 years of follow-up (SIR 0.63, 95% CI 0.43–0.90), and was maintained during 
the whole follow-up. Expressed as absolute numbers, 3-6 invasive ovarian 
cancers were prevented per 10 000 LNG-IUS users followed for 10 years. 
The risk of borderline ovarian tumors was also significantly decreased among 
LNG-IUS users (SIR 0.76, 95% CI 0.57–0.99). Significant differences between 
histology-specific SIRs of borderline tumors did not exist (Table 11). 
Expressed as absolute numbers, five prevented invasive ovarian cancers were 
observed per 1000 LNG-IUS users followed for 10 years. 
A total of seven cases of PFTC were registered among LNG-IUS users during 
the study period. The risk of PFTC among LNG-IUS users was comparable 















































































































































































































































































































































































































































































































































































































































































































































































































































































































Other cancers (Study I) 
 
In addition, LNG-IUS users had a significantly lower risk of lung cancer (SIR 
0.68, 95% CI 0.49–0.91) and pancreatic cancer (SIR 0.50 (95% CI 0.28–0.81). 
The risk of cervical cancer among LNG-IUS users did not differ from that of 






Cancer risk after endometrial ablation 
Endometrial ablations in Finland 
 
Before the detailed results for cancer risks and hysterectomies after 
endometrial ablations (Study IV), I present some results of the background 
data characterizing the endometrial ablations performed in Finland during 
1997–2014. 
During the study period 1997–2014, a total of 5591 endometrial ablations were 
performed in Finland. The number of endometrial ablations has been growing 
during the 2000s in Finland (Figure 11). 
 





There were differences between the hospital districts in the incidences of 
performed endometrial ablations during 1997–2014 in Finland. The highest 
incidence of endometrial ablation was in the hospital district of Satakunta 
(28/100 000 women-years), and the lowest was in Ahvenanmaa (1/100 000 


























Figure 12. Incidence of endometrial ablations by hospital district 




Endometrial cancer and other cancers (Study IV) 
 
 
During the study period 1997–2014 with 39 892 women-years of follow-up, a 
total of 154 cancers were diagnosed among the study cohort of 5484 
endometrial ablation treated women in Finland (Table 12). The SIRs for all 































































































































































Table 12. Observed and expected number of cancer cases and standardized incidence ratios 
(SIRs), with 95% confidence interval (CI), among Finnish women treated with endometrial 
ablation at ages 30–49 years. Follow-up 1997–2014. 
Age (years) n Women-
years 
OBS EXP SIR 95% CI 
30–34 329 558 0 0.5 0.00 0.00–7.44 
35–39 1 286 3 389 2 4.8 0.42 0.05–1.50 
40–44 2 151 9 408 27 21.5 1.26 0.83–1.83 
45–49 1 718 13 613 53 52.8 1.00 0.75–1.31 
50–54 0 9 086 42 51.1 0.82 0.59–1.11 
over 55 0 3 839 30 29.2 1.03 0.69–1.47 
Total 5 484 39 892 154 160.0 0.96 0.82–1.13 
EXP = expected, OBS = observed. 
 
 
Table 13. Diagnosed cancer cases and standardized incidence ratios (SIRs), with 95% 
confidence interval (CI), among women treated with endometrial ablation during 1997–2014 at 
ages 30–49 years in Finland. 
Time since 
endometrial 
ablation Cancer cases SIR 95% CI 
0–0.99 years 13 0.94 0.50–1.61 
1–4.99 years 54 1.00 0.75–1.31 
5 years and over 87 0.94 0.76–1.16 





Of all diagnosed cancers among the endometrial ablation treated women, 3 
were endometrial cancers. The SIR for endometrial cancer among endometrial 
ablation treated women was 0.56 (95% CI 0.12–1.64; 5.3 expected cases). Of 
the endometrial cancers, 2 cases were local and one was of unknown location. 
The SIR for ovarian cancer was 0.59 (95% CI 0.12–1.72; 3 observed compared 
with 5.1 expected cases), and for cervical cancer 0.78 (95% CI 0.10–2.83; 2 






Figure 13. Standardized incidence ratios (SIRs), with 95% 
confidence interval (CI), among women treated with 
endometrial ablation during 1997–2014 at ages 30–49 years in 







Among the endometrial ablation treated women, a total of 67 breast cancers 
were diagnosed during the follow-up (SIR 0.86, 95% CI 0.67–1.09; 77.9 
expected cases), which was comparable with that of the general population 
(Figure 13). 
 
Hysterectomy after endometrial ablation (Study IV) 
 
A total of 1086 women (19.8%) underwent hysterectomy in the endometrial 
ablation cohort during the follow-up (mean 7.3 years, maximum 18 years). 
Most hysterectomies were among those 45–49 years old (Figure 14). The 
mean age at hysterectomy was 44.7 ± 5.2 years in the endometrial ablation 
cohort and 44.4 ± 5.7 years in the controls. 
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Figure 14. Hysterectomies by age group among endometrial 




Most hysterectomies were performed during the first few years after 
endometrial ablation (Figure 15). Compared with the controls, endometrial 
ablation treated women had a 3.6-fold risk of hysterectomy (HR 3.63, 95% CI 
3.32–3.96). 
Figure 15. Time interval from endometrial ablation to 




The most frequent indications for hysterectomy after endometrial ablation 
were HMB (47.8%), leiomyomas (18.9%), and other not specified indications 



























































Figure 16. Indication of postablation hysterectomy in the 





Risk factors for postablation hysterectomy 
 
Risk of postablation hysterectomy was highest among women with leiomyoma 
diagnosis at endometrial ablation (HR 1.78, 95% CI 1.03–3.10), or who were 
younger than 35 years at the time of endometrial ablation (HR 1.44, 95% CI 
1.15–1.81). In addition, the risk of hysterectomy was significantly increased 
among women with at least two prior cesarean deliveries (HR 1.27, 95% CI 
































Table 14. Predictors for hysterectomy after endometrial ablation. 
Variable Adjusted HR (95% CI)¹ 
Age at index date, years 
30–34 1.44 (1.15–1.81)** 
35–39 1.15 (0.99–1.34) 
40–44 1 
45–49 0.90 (0.77–1.05) 
Number of deliveries before index date 
0 1 
1 1.06 (0.77–1.46) 
2 0.82 (0.62–1.10) 
≥ 3 0.91 (0.68–1.20) 
Number of cesarean sections before index date 
0 1 
1 1.09 (0.91–1.32) 
≥ 2 1.27 (1.04–1.55)* 
History of tubal sterilization before index date 
No 1 
Yes 1.15 (1.01–1.32)* 
Indication of endometrial ablation 
Heavy menstrual bleeding 1 
Leiomyomas 1.78 (1.03–3.10)* 
Endometriosis/Adenomyosis 1.44 (0.64–3.24) 
Endometrial hyperplasia 1.35 (0.64–2.85) 
Other abnormal uterine bleeding 0.66 (0.30–1.47) 
Dysmenorrhea 1.06 (0.47–2.37) 
Other 0.83 (0.71–0.98)* 
Follow-up time, years since index date 
0–0.99 4.44 (3.67–5.36)*** 
1–4.99 2.43 (2.03–2.91) 
5–9.99 1 
10–14.99 0.68 (0.48–0.98)* 
≥ 15 1.14 (0.58–2.23) 
  
 
Index date, the date of endometrial ablation and the beginning of the follow-up. 
CI = confidence interval, HR = hazard ratio. 
* p < 0.05 
** p < 0.01 
*** p < 0.001 






Intrauterine treatment for HMB in the form of LNG-IUS or endometrial 
ablation has been extensively used for the last two decades but its effect on 
women’s later cancer risk has been only poorly studied. The finding of the 
crucial role of progestins in the carcinogenesis of the female reproductive 
organs, especially of the breast and uterus, has raised questions about the 
effect of long-term hormonal treatments used during fertile years. 
Breast cancer is the most frequent female cancer, and its incidence has been 
increasing in many countries (Ferlay et al. 2012). It has been estimated that 
up to one in eight women will be diagnosed with breast cancer during their 
lifetime, and 25% of them will be under 50 years of age at the time of diagnosis 
(Ferlay et al. 2012, Rojas and Stuckey 2016) (www.cancer.fi). Due to the 
emerging role of LNG-IUS as a primary treatment for HMB even at young 
ages, the effect of long-term use of levonorgestrel on the risk of endometrial 
cancer or breast cancer is of major interest. On the other hand, due to the 
increasing prevalence of obesity already at young ages, decreasing parity, and 
the resulting increase in the incidence of endometrial cancer also in the 
premenopausal population (Arnold et al. 2015, Kamal et al. 2016), the possible 
protective effect of intrauterine levonorgestrel has to be elucidated.   
Due to the possible negative effects of hormonal treatments on cancer risks 
(Bassuk and Manson 2015), many women desire non-hormonal options for 
the treatment of HMB. The newer non-hysteroscopic endometrial ablation 
techniques, which are safe and easy to perform in an outpatient setting and 
are as effective for HMB as LNG-IUS, have become more popular than before 
in many countries (Reid 2007, Wortman et al. 2015). However, the effect of 
the destruction of the endometrium by endometrial ablation on later cancer 
risk, especially on endometrial or breast cancer risk, is not well known and 
needs to be assessed. 
We conducted four national studies to evaluate the risk of cancer, especially of 




treated with endometrial ablation during their reproductive years. The 
national nature of the studies was important in particular for examining the 
effect of LNG-IUS use on cancer risk as LNG-IUSs considered globally have 
been on the market for the longest time in Finland, and the prevalence of LNG-
IUS use is very high in Finland (Lindh et al. 2017). Ideally, the possible risk 
evaluations on LNG-IUS use and cancer risk should be studied in each 
country, as the prescription policies, genetic landscapes due to ethnic 
backgrounds, and lifestyle factors among women may vary between regions. 
All studies of this thesis were register studies based on Finnish law-based 
health-care registers. The register-based studies were well suited to test the 
hypotheses on cancer risks. Also, conducting a prospective randomized 
controlled study would not be a realistic option, as it would take decades to 
provide information on cancer risks, would be difficult to conduct, be 
expensive, and even be unethical to expose young women to a hormonal 
method with contraceptive properties for a long time. With the data of the 
Finnish health registers, we were able to study the impact of LNG-IUS use on 
cancer risks in the largest patient series so far reported. 
With the first three cohort studies, we were able to test our primary hypotheses 
of decreased risk of endometrial and ovarian cancers among LNG-IUS users. 
When the unexpected finding of an increased risk of breast cancer among 
LNG-IUS users was found in the first study, and also the second study 
supported the previous findings, we decided to conduct a study among women 
with HMB but treated non-hormonally with endometrial ablation and assess 
their risk of breast cancer and other cancers, especially endometrial cancer. 
 
LNG-IUS and breast cancer risk 
We observed that risk of breast cancer among women treated with LNG-IUS 
for HMB was increased by 19% compared with the background population. 
This was a novel and unexpected finding. In absolute numbers, this means 2–
4 excess cases of breast cancer per 1 000 LNG-IUS users followed for 10 years. 
Previously published studies had not observed an increase in the risk of 




Dinger et al. 2011). Moreover, neither did a recent case-control study observe 
elevated risk of breast cancer among premenopausal women with prior LNG-
IUS use (Heikkinen et al. 2016a). However, in the first published study on the 
topic (Backman et al. 2005), the follow-up was only 10 years, which is probably 
too short to detect differences in cancer incidence. Also, the comparisons of 
cancer incidence in that study were unusual, as the breast cancer incidence of 
the LNG-IUS users during the whole study period was compared with the 
breast cancer incidence of the background population for a single year 
(Backman et al. 2005). Two later studies (Dinger et al. 2011, Heikkinen et al. 
2016a) were case-control studies, which carry significant limitations especially 
due to recall, misclassification, and selection biases. Women who are 
diagnosed with cancer might be more prone than healthy controls to report 
any use of hormonal preparations, and also misclassify the preparations they 
have used. Also, some of the breast cancer patients may have already died due 
to the most aggressive diseases, and were thus missed from the analysis. 
In our study, a significant increase in breast cancer incidence among LNG-IUS 
users was observed during the first years of follow-up among women aged 50–
54 years, but after 5 years, the risk was significantly elevated also in the 
younger age groups. The increased risk of breast cancer was most evident – 
40% higher than in the general population – among women with two or more 
LNG-IUS purchases. In absolute numbers, this means approximately an 
excess of 7 breast cancers among 1 000 women with a history of two or more 
LNG-IUS purchases and followed for 10 years. The risk of both most common 
histological subtypes of breast cancer – ductal and lobular – was increased 
among LNG-IUS users. Moreover, the risk of lobular subtype, generally 
considered to be associated with the use of exogenous hormones, was 73% 
higher among LNG-IUS users than among other women. This means one extra 
case of lobular breast cancer among 1 000 LNG-IUS users followed for 10 
years. In LNG-IUS users, during the first years of follow-up, the risk of 
localized breast cancer was higher than in the general population, but after 





Altough it is possible that the mechanism explaining increased risk of breast 
cancer among LNG-IUS users is other than levonorgestrel per se, a causal 
effect of levonorgestrel on breast cancer promotion cannot be excluded. 
Several plausible biological mechanisms behind the possible adverse effect of 
levonorgestrel in the mammary tissue exist. Levonorgestrel is released 
continuously from the LNG-IUS, and continuous progestin administration has 
been associated with a higher risk of breast cancer compared with cyclical 
administration of progestin in studies among postmenopausal women 
(Lyytinen et al. 2009). Levonorgestrel may also have a proliferative effect on 
breast cells. It has been reported that the mitotic activity in breast cells 
obtained from women using levonorgestrel-containing contraceptive pills was 
significantly higher during the first week of the menstrual cycle than in women 
with a natural cycle (Garcia y Narvaiza et al. 2008). Additionally, 
levonorgestrel is the most potent progestin used in hormonal preparations 
(Dorflinger 1985), which could explain possible actions even in low systemic 
concentrations. 
 
LNG-IUS and endometrial cancer risk 
Our study was the first to show that LNG-IUS use during fertile years is 
associated with a decreased risk of endometrial cancer. Among the LNG-IUS 
users, after one purchase of LNG-IUS, the risk of endometrial adenocarcinoma 
was 54% lower than that of the general population. In absolute numbers, 3–6 
cases of endometrial adenocarcinoma are prevented among 10 000 women 
using LNG-IUS and followed for 10 years. The protective association of LNG-
IUS use against endometrial cancer was even stronger after two or more 
purchases of LNG-IUS, potentially reflecting the effect of long-term use of 
LNG-IUS. The incidence of endometrial adenocarcinoma among women with 
two or more purchases of LNG-IUS was 75% lower than in the general 
population. This means that approximately 8 cases of endometrial 
adenocarcinomas are prevented per 10 000 women with two or more LNG-
IUSs and followed for 10 years. Our finding is in line with a study on 
postmenopausal women using LNG-IUS (Jaakkola et al. 2011). The risk of 




users (Felix et al. 2015), and our results indicate that the risk is significantly 
lower with the hormonal intrauterine system. 
In our study among fertile-aged women, virtually all endometrial cancers were 
endometrial adenocarcinomas possibly due to the young age distribution of 
our study population. During the past decade, endometrial cancer 
classification has changed, and it has been established that endometrial cancer 
is a heterogeneous group of tumors with distinct morphological, genetic, and 
risk characteristics with different prognoses (Murali et al. 2014). The effect of 
LNG-IUS use on the risk of specific endometrial cancer molecular subtypes 
with different mutational landscapes should be separately studied. 
 
LNG-IUS use and risk of ovarian cancer or primary fallopian tube 
carcinoma 
LNG-IUS use in relation to ovarian cancer was analyzed overall and separately 
according to tumor histology. The total risk of invasive ovarian cancer among 
LNG-IUS users was decreased by 41% compared with that of the general 
population of similar age. In absolute numbers, this means that 3–6 cases of 
invasive ovarian cancer are prevented among 10 000 LNG-IUS users followed 
for 10 years. The decrease in ovarian cancer risk was observed in the first years 
after the LNG-IUS purchase, and it was maintained during the whole follow-
up. The risk of borderline ovarian tumors, precursors for invasive cancers, was 
also significantly lower among LNG-IUS users than among the other women. 
No previous studies exist on the effect of LNG-IUS use on ovarian cancer risk 
among premenopausal women, but a neutral effect was observed in a study 
among postmenopausal women with ET combined with LNG-IUS (Koskela-
Niska et al. 2013b). However, the number of cases in that study was probably 
too sparse to detect significant associations. 
In terms of histological subtypes, the risk decrease was largest for mucinous 
ovarian cancers among LNG-IUS users. The risk was decreased by 51% for 
mucinous invasive ovarian cancer compared with the general population. Also, 
the incidence of borderline ovarian tumors among LNG-IUS users was lower 




of follow-up. Before our studies, no previous reports existed on the effect of 
LNG-IUS on the risk of mucinous ovarian tumors. 
Mucinous ovarian cancer is a distinct subtype of ovarian cancer, as it is 
suggested to originate from cells of gastrointestinal origin (Kelemen and Kobel 
2011). Also, the risk factors for mucinous ovarian cancer differ from the other 
ovarian cancers (Kelemen and Kobel 2011). COCs have not been reported to 
provide protection from mucinous ovarian tumors (Schuler et al. 2013, 
Fortner et al. 2015), which may be reflected by the lower PR expression of 
mucinous tumors compared with the other ovarian cancers (Diep et al. 2015). 
Among postmenopausal women, the effect of HT on mucinous ovarian cancer 
risk is inconsistent (Yang et al. 2012, Koskela-Niska et al. 2013a, Collaborative 
Group on Epidemiological Studies of Ovarian Cancer et al. 2015, Fortner et al. 
2015). Thus, our finding of a protective association of LNG-IUS use with 
mucinous ovarian cancer can be mediated by other mechanisms than the 
direct effect of levonorgestrel. 
The risk of ovarian endometrioid carcinoma was almost halved among LNG-
IUS users compared with the general population. Plausible biological 
mechanisms explaining the protective effect of LNG-IUS exist. Endometrioid 
ovarian cancer seems to originate from endometriotic cells and abundantly 
expresses PRs (Diep et al. 2013, Nezhat et al. 2015). LNG-IUS use significantly 
decreases menstrual bleeding and thus minimizes retrograde transportation 
of blood including endometriotic cells, growth factors, as well as inflammatory 
or carcinogenic factors into the fallopian tubes (Cramer and Xu 1995, Lethaby 
et al. 2015). Additionally, LNG-IUS is an efficient treatment for endometriosis, 
a risk factor for endometrioid ovarian cancer (Dunselman et al. 2014, Nezhat 
et al. 2015). Also, it can be hypothesized that the protective effect of LNG-IUS 
may be mediated via a direct progestin effect. The decreased ovulation theory 
probably does not explain the effect of LNG-IUS on ovarian cancer risk as 
LNG-IUS does not have any significant effect on ovarian function, or suppress 
ovulations (Nilsson et al. 1984). 
The risk of clear cell carcinoma, which is also suggested to be of endometrial 




to the rarity of clear cell carcinomas and the low number of cases in our study, 
robust conclusions cannot be made. 
The risk of the most common ovarian cancer, serous carcinoma, was 25% 
lower among LNG-IUS users than in the background population. A limitation 
of our study was that we were not able to distinguish serous ovarian 
carcinomas according to the new classification (Prat and FIGO Committee on 
Gynecologic Oncology 2014, Kurman et al. 2014) into high-grade and low-
grade categories but analyzed all serous ovarian carcinomas as one group. 
High-grade serous ovarian cancer originates from the distal fallopian tubes 
and is the most lethal ovarian cancer (Kurman and Shih 2010, Crum et al. 
2012). Low-grade serous ovarian cancer subtype has more indolent character, 
and expresses higher levels of PRs compared with high-grade serous subtype 
(Kurman and Shih 2010, Diep et al. 2015). Due to the heterogeneous character 
of high-grade and low-grade serous ovarian cancers, more separate studies on 
the effect of LNG-IUS use for the serous ovarian cancer subtypes are needed. 
The incidence of PFTC among LNG-IUS users was comparable with that of the 
general population. No other reports have been published on LNG-IUS use at 
reproductive ages and later PFTC risk. Among postmenopausal women with 
long-term estrogen treatment combined with LNG-IUS use for more than 
5 years, an increased risk of PFTC has been reported (Koskela-Niska et al. 
2015). However, due to the rarity of PFTC, more studies with larger cohorts 
are needed. 
 
LNG-IUS use and risks of other cancers 
The risk of pancreatic cancer among LNG-IUS users was only one-half of that 
in the background population. The incidence of pancreatic cancer is markedly 
lower among women than among men (www.cancerregistry.fi) (Ilic and Ilic 
2016). Female hormone exposure may play a role in this, but more likely 
explanations may be related to the confirmed risk factors for pancreatic 
cancer, most importantly smoking. The women in our LNG-IUS cohort also 
had significantly lower lung cancer incidence than the background population, 




should also be taken into account when interpreting the SIRs of the other 
smoking-related cancers among the LNG-IUS users. 
In our study, the risk of cervical cancers, including squamous cell cancers and 
adenocarcinomas of the cervix, did not differ between LNG-IUS users and the 
general population. Persistent high-risk HPV infection is the cause of cervical 
cancer, but only one previous report on the role of LNG-IUS as a potential 
cofactor exists. In that small observational study, LNG-IUS use was not 
associated with precancerous cervical atypia (Lessard et al. 2008). Non-
hormonal IUD use has been reported to be associated with a halved risk of 




Endometrial ablation and cancer risk 
In the study on endometrial ablation treated Finnish women, we found that 
the total cancer risk of these women was similar to that of the background 
population. 
The risk of breast cancer among women treated with endometrial ablation was 
not increased and was comparable with that of other Finnish women. This is 
in line with the only previous study assessing breast cancer incidence after 
endometrial ablation (Cooper et al. 2011). A similar incidence of breast cancer 
to that of other women suggests that HMB per se is not a risk factor for breast 
cancer. This finding should be taken into account when interpreting the results 
of breast cancer risk among women using LNG-IUS for HMB. 
We found that the risk of endometrial cancer was not altered after endometrial 
ablation. This is a reassuring finding as traditionally premenopausal AUB has 
been considered to be associated with an increased risk of endometrial cancer 
(Soliman et al. 2005). Moreover, according to a recent systematic review 
(Pennant et al. 2017), premenopausal AUB is not associated with increased 
prevalence of endometrial cancer (1.31%, 95% CI 0.96–1.80), and the 
prevalence of endometrial cancer was even lower among women with HMB 




of women diagnosed with endometrial cancer after endometrial ablation was 
0.05%, which is even lower (Pennant et al. 2017), and is similar to that of a 
large Scottish study (Cooper et al. 2011). This suggests that women suffering 
from HMB are not at an increased risk of endometrial cancer.  
In our study, the majority of endometrial ablation treated women were parous, 
which is a protective factor against breast cancer and endometrial cancer. If 
the endometrial ablation treated women had more pregnancies than the 
background population, the risk estimates for breast cancer and endometrial 
cancer would be too low. 
The risk of ovarian cancer or cervical cancer after endometrial ablation was 
not increased in our study. Only one previous report on the incidence of these 
cancers after endometrial ablation exists (Cooper et al. 2011), and our results 
are in line with that study. However, based on the small numbers of observed 
ovarian and cervical cancers in our study, robust conclusions cannot be made. 
 
Hysterectomy after endometrial ablation 
In our study, most women (80%) treated with endometrial ablation did not 
need a later hysterectomy, which is comparable with the results from other 
studies based on second-generation endometrial ablations. In our study, the 
most common indication for postablation hysterectomy in half of the cases was 
HMB, and the second most common cause was leiomyomas in every fifth case. 
The risk of hysterectomy was highest during the first 2 years, but remained 
higher than that of other women during the whole follow-up. Compared with 
the other women of similar age, women treated with endometrial ablation had 
an almost 4-fold risk of hysterectomy. The significantly elevated risk of 
hysterectomy during the first couple of years after endometrial ablation has 
also been observed in other studies (Cooper et al. 2011, Shavell et al. 2012). 
The risk of postablation hysterectomy was highest among those women with 
leiomyomas as the main indication at endometrial ablation. The role of 
leiomyomas as a risk factor for failure of endometrial ablation is inconsistent. 
Leiomyomas have been a significant risk factor for hysterectomy in some 




(Longinotti et al. 2008, El-Nashar et al. 2009, Shavell et al. 2012). However, 
the role of leiomyomas as a risk factor is difficult to interpret, as most studies 
have not reported the sizes or locations of the leiomyomas. In our study, age 
younger than 35 years at ablation was also a significant risk factor, which is 
also observed in several other studies (Longinotti et al. 2008, El-Nashar et al. 
2009, Shavell et al. 2012, Bansi-Matharu et al. 2013). Additionally, women 
with two or more prior cesarean sections before endometrial ablation were at 
significant risk of later hysterectomy, which is reported in some studies 
(Shavell et al. 2012, Wishall et al. 2014). Also, a prior sterilization before 
endometrial ablation was a risk factor for postablation hysterectomy in our 
study. Results from the other studies on sterilization as a risk factor are 
inconclusive (El-Nashar et al. 2009, Shavell et al. 2012, Wishall et al. 2014). 
Moreover, this finding should be interpreted carefully, as the majority of 
women treated with endometrial ablation were sterilized in our study. This 
reflects the policy of high recommendation of sterilization before endometrial 
ablation in Finland. 
 
Endometrial ablations in Finland 
According to our findings, there are significant variations in the incidence of 
endometrial ablations by different hospital districts in Finland. This was an 
unexpected finding and may reflect variations in clinical practices in the 
management of patients with HMB. As newer non-hysteroscopic endometrial 
ablations have shown to be similarly effective for HMB compared with LNG-
IUS, have a good safety profile, and most endometrial ablation treated women 
seem to avoid later hysterectomy, a new evidence-based national guideline for 
the treatment of HMB is needed. 
Study strengths and limitations 
 
It is important to understand the strengths and limitations of observational 
register-based studies before drawing conclusions. Our study had many 




study setting. We also had detailed and complete information on LNG-IUS 
reimbursements since 1994 from the Medical Reimbursement Register as well 
as information on endometrial ablations from the Hospital Discharge 
Register, which reduces selection bias. However, selection bias cannot be 
excluded, as LNG-IUSs were used for HMB and these women might represent 
a special population with different intrinsic risk factors (i.e., anovulation, 
hyperestrogenism) to the general population. We also had a long follow-up in 
the studies, which is mandatory in epidemiological cancer research as cancer 
development from precursors to detectable invasive tumors takes years. With 
the high-quality register data from our national law-based registers, we had 
virtually no losses to follow-up. We also had complete information on surgical 
operations from the Hospital Discharge Register, cancer diagnoses from the 
Finnish Cancer Registry, and information on emigration and deaths from the 
Population Register Centre. This makes recall bias impossible. 
There are also many limitations in this type of study based on registers, and 
thus the results should be interpreted with caution. Register-based studies are 
observational in nature and can only give information on the associations 
between risk factors and cancers. In a cohort study setting, the control of all 
potential confounding factors (e.g., age at menarche, use of other exogenous 
hormones, lifestyle factors, family history of cancer) is difficult, and 
confirmation of causality must usually be confirmed by other study settings. 
In the LNG-IUS studies (Studies I–III) we could not verify that the LNG-IUS 
insertion truly happened, but it is likely, as the LNG-IUSs in the study 
population were prescribed for the treatment of HMB, women had to cover the 
costs of the LNG-IUS purchase from their own pocket, and only a minor 
portion of the price was reimbursed. Repeat purchases are also likely to reduce 
this potential bias. Neither did we have data on the duration of LNG-IUS use 
after insertion. However, most women continue LNG-IUS therapy long-term 
after insertion, as the continuation rate at 48 months has been reported to be 
over 70% in women aged over 29 years (Diedrich et al. 2015). Whether the 
effect of LNG-IUS use disappears as time elapses from the discontinuation of 
use, is unknown. In COC users, the excess risk of breast cancer has been 




Bassuk and Manson 2015), but the protective effect on the endometrium and 
ovaries remains for decades (Schlesselman 1997, Collaborative Group on 
Epidemiological Studies of Ovarian Cancer 2008, Havrilesky et al. 2013). 
We did not have information on COC use or parity in the LNG-IUS studies. 
Use of COCs may modify the risk of cancers such as breast, endometrial, and 
ovarian cancer. LNG-IUS users might be more commonly parous and the 
increase in parity is associated with a decreased risk of breast, endometrial, 
and ovarian cancer. If that was the case, the risk estimates for these cancers 
would be too low. We did not have data on performed mammographies among 
the LNG-IUS users. In Finland, organized mammography screening is not 
offered for women under 50 years. However, according to a recent study 
(Heikkinen et al. 2016b), approximately two-thirds of women have had 
mammographies before the organized screening. Whether LNG-IUS users are 
overrepresented in those women with opportunistic mammographies, is 
unknown. However, our finding that SIRs for ductal carcinoma in situ (DCIS) 
lesions, most of which are detected by mammography, were lower than for 
invasive breast cancers, suggested that the frequency of mammographies 
among LNG-IUS users is comparable with that of other women. A surveillance 
bias could not be totally excluded, as breast tenderness is common among 
LNG-IUS users (Leminen et al. 2012) and may lead to more frequent clinical 
breast examinations. Regarding the assessment of ovarian cancer risk, a 
surveillance bias is also possible. LNG-IUS users often have transient ovarian 
cysts (Lethaby et al. 2015), which also may result in more frequent and closer 
monitoring of these women in health care. In such cases, more borderline 
tumors and invasive ovarian cancers might be diagnosed. 
One shortcoming of this study is that the LNG-IUS users (Studies I–III) and 
endometrial ablation treated women (Study IV) were compared with a 
reference population which also included the corresponding study group (i.e., 
LNG-IUS users or endometrial ablation treated women) and women with 
previous hysterectomy or salpingo-oophorectomy. Therefore, the risk 
estimates are lower than they would be if the reference population had been 
without women who had undergone these surgical operations, without users 




diluting effect is small due to the relatively small number of LNG-IUS users 
and endometrial ablation treated women in the background population. 
Despite the limitations, a large cohort study based on high-quality registers is 
a suitable way to assess cancer risks among a fertile-aged population. It would 
never be possible to conduct a prospective randomized study among young 
women with LNG-IUS at cohort size and with sufficient follow-up to evaluate 








Both LNG-IUS and endometrial ablation have been shown to be equally 
effective on HMB as a means of reducing menstrual blood loss and regarding 
patient satisfaction (Marjoribanks et al. 2016). Both these treatments are 
superior in cost-effectiveness compared with hysterectomy. The decision of 
how to treat HMB depends on the woman’s desire to preserve fertility, her 
acceptance of and suitability for hormonal or surgical treatment, and risk–
benefit estimations. 
The most important finding of our studies was the contrasting associations of 
LNG-IUS use on endometrial cancer and breast cancer risk. The leading aim 
of our studies was to assess the risk of endometrial cancer among LNG-IUS 
users. The protective effect of LNG-IUS use against endometrial cancer among 
premenopausal women was a novel but expected finding. Based on this 
finding, fertile-aged women with known risk factors for endometrial cancer 
(i.e., obesity, anovulatory HMB) could potentially benefit from intrauterine 
levonorgestrel treatment with regards to endometrial protection. However, 
future studies are needed to assess the molecular biological effects of 
intrauterine levonorgestrel. Recent data indicate that endometrial cancer is a 
heterogenic disease (dualistic pathway) with different mutational and 
hormone receptor landscapes (Murali et al. 2014) and it is possible that the 
effect of progestins on different subtypes of endometrial cancer may vary. 
The finding of increased risk of breast cancer among fertile-aged LNG-IUS 
users was a novel and unexpected finding. As breast cancer is globally a vast 
burden and the most common female cancer, all factors increasing breast 
cancer risk should be thoroughly elucidated. A slight increase in breast cancer 
risk can have a significant impact at the population level. Previously it has been 
thought that the low level of levonorgestrel released from LNG-IUS into the 
systemic circulation may not affect the breast, and even breast cancer patients 
have used LNG-IUS. However, both our findings of elevated breast cancer 
incidence among fertile-aged women and the previous findings among 




a new light. More studies are needed, especially on different molecular 
subtypes (i.e., steroid hormone receptor contents, HER2 status) of breast 
cancers among LNG-IUS users. In addition, there is an urgent need for studies 
on the safety of LNG-IUS use among breast cancer survivors. 
Ovarian cancer is also a heterogeneous disease, and the effect of progestins on 
protection from this cancer varies. Our result showing the protective 
association of LNG-IUS use during fertile years on the risk of epithelial ovarian 
cancers was novel, which necessitates future studies on the effects of 
levonorgestrel on ovarian carcinogenesis, especially on the most deadly type, 
serous high-grade ovarian cancer. 
Of note is that cancer development usually takes years and many factors 
associated with increased cancer risk are modifiable (i.e., obesity, smoking, 
and excess use of alcohol). It has been estimated that 30% of breast cancers 
could be preventable by maintaining a healthy lifestyle (Howell et al. 2014). It 
is thus especially important to identify early in life those women at high risk of 
cancer who would benefit from the preventive efforts. Given the well-
recognized increase of endometrial cancer incidence as well as the epidemic of 
obesity in the Western world in the last decades, even a slight decrease in 
endometrial cancer risk due to LNG-IUS use could have a public health 
importance. This finding encourages further studies on the use of LNG-IUS 
for the primary prevention of endometrial cancer in populations most at risk. 
HMB is a common complaint and hormonal treatment with LNG-IUS for 
HMB is in many cases the best option. Some hormonal treatments of HMB 
may affect later cancer risk but it is unknown whether the effect is transient. 
It is important to weigh the beneficial effects of LNG-IUS and mini-invasive 
surgery (endometrial ablation) for HMB against the potential risks, and decide 





On the basis of the studies included in this thesis, the following conclusions 
can be drawn: 
 
1. The use of LNG-IUS for HMB is associated with a significantly 
decreased risk of endometrial cancer. 
 
2. The risk of breast cancer is higher among women using LNG-IUS for 
HMB than in the background population. 
 
3. Lobular breast cancer is associated most strongly with LNG-IUS use, 
but also the risk of the ductal subtype is elevated among LNG-IUS users. 
 
4. The risk of all epithelial ovarian cancers is decreased among women 
using LNG-IUS for HMB. The risk is most decreased for mucinous, 
endometrioid, and serous subtypes of ovarian cancer. The risk is also 
decreased for borderline ovarian tumors. 
 
5. The risk of endometrial cancer after endometrial ablation is similar to 
that of the background population. 
 
6. The risk of breast cancer among women with endometrial ablation is 
not increased. 
 
7. The majority (80%) of women do not need a hysterectomy after 
endometrial ablation. 
 
8. The risk of postablation hysterectomy is highest during the first years 
after endometrial ablation. Risk factors for hysterectomy are 
leiomyomas, age under 35 years, and a history of prior cesarean 
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